Patent Grant
12098417
This application contains a Sequence Listing that has been submitted electronically as an XML file named “47706-0208003_SL_ST26.XML.” The XML file, created on May 10, 2023, is 591,820 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety.
Cells within a tissue have differences in cell morphology and/or function due to varied analyte levels (e.g., gene and/or protein expression) within the different cells. The specific position of a cell within a tissue (e.g., the cell's position relative to neighboring cells or the cell's position relative to the tissue microenvironment) can affect, e.g., the cell's morphology, differentiation, fate, viability, proliferation, behavior, signaling, and cross-talk with other cells in the tissue.
Spatial heterogeneity has been previously studied using techniques that typically provide data for a handful of analytes in the context of intact tissue or a portion of a tissue (e.g., tissue section), or provide significant analyte data from individual, single cells, but fails to provide information regarding the position of the single cells from the originating biological sample (e.g., tissue).
Understanding spatial heterogeneity in the context of immune cell clonotypes (e.g., T-cell receptor, B-cell receptor) within an intact biological sample, or a portion thereof, can give insight into which cells or cell-types specific T-cell or B-cell clonotypes may be interacting. Single-cell methods can identify clonotype populations, but fail to link the spatial organization of immune cell clonotypes within a biological sample.
A fundamental understanding of spatial heterogeneity with respect to T-cell receptor (TCR) and B-cell receptor (BCR) clonotypes within a biological sample is needed to understand which cells a TCR or BCR may interacting with, the identity of TCR and/or BCR clonotypes in a given biological sample, or the identity of TCR and/or BCR clonotypes that are autoreactive in different autoimmune disorders. Numerous single-cell sequencing approaches can identify TCR and BCR clonotypes from a biological sample, however, at present methods are needed to link TCR and BCR sequences to spatial locations within a biological sample. Additionally, identifying the clonal regions, that is, regions defined by the places where variable (V), diverse (D), and joining (J) segments join to form the complementarity determining regions, including CDR1, CDR2, and CDR3, which provide specificity to the TCRs and/or BCRs, is important in understanding the TCR and BCR biological interactions. By coupling clonal information to spatial information it is possible to understand which T-cell and B-cell clonotypes may be specifically interacting with given cell types within a biological sample.
Provided herein are methods for determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample. Some embodiments of any of the methods described herein include capturing transcripts to identify an immune cell clonotype. Some embodiments of any of the methods herein include generating a nucleic acid library from captured transcripts. Some embodiments of any of the methods described herein include enriching analytes of interest in the nucleic acid library, including analytes to identify an immune cell clonotype.
Provided herein are methods for determining the presence and/or abundance of an immune cell receptor at a location in a biological sample. Some embodiments of any of the methods described herein include capturing analytes to identify an immune cell receptor. Some embodiments of any of the methods described herein include generating a nucleic acid library from captured analytes. Some embodiments of any of the methods described here include enriching analytes of interest in the nucleic acid library, including analytes to identify an immune cell receptor.
Thus provided herein are methods for determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample, the method including: (a) contacting a biological sample with an array including a plurality of capture probes, where a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that binds to a nucleic acid encoding an immune cell receptor of the immune cell clonotype; and (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell clonotype at a location in the biological sample.
In some embodiments, the immune cell clonotype is a T cell clonotype. In some embodiments, the T cell clonotype is a T cell receptor alpha chain. In some embodiments, the capture domain binds to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the T cell receptor alpha chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor alpha chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the T cell receptor alpha chain.
In some embodiments, the immune cell receptor is a T cell receptor beta chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the T cell receptor beta chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor beta chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the T cell receptor beta chain.
In some embodiments, the immune cell clonotype is a B cell clonotype. In some embodiments, the B cell clonotype is an immunoglobulin kappa light chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the immunoglobulin kappa light chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the immunoglobulin kappa light chain. In some embodiments, the B cell clonotype is an immunoglobulin lambda light chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the immunoglobulin lambda light chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the immunoglobulin lambda light chain. In some embodiments, the B cell clonotype is an immunoglobulin heavy chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the immunoglobulin heavy chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin heavy chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the immunoglobulin heavy chain.
In some embodiments, the capture domain binds a poly(A) sequence of a nucleic acid encoding an immune cell clonotype. In some embodiments, the capture domain binds to a nucleic acid sequence encoding a T cell clonotype. In some embodiments, the T cell clonotype is a T cell receptor alpha chain, a T cell receptor beta chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding CDR3 of the T cell receptor alpha chain, a sequence encoding CDR3 of the T cell receptor beta chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding one or both of CDR 1 and CDR2 of the T cell receptor alpha chain, a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor beta chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding a full-length variable domain of the T cell receptor alpha chain, a sequence encoding a full-length variable domain of the T cell receptor beta chain, and combinations thereof.
In some embodiments, the capture domain binds to a nucleic acid encoding a B cell clonotype. In some embodiments, the B cell clonotype is an immunoglobulin kappa light chain, an immunoglobulin lambda light chain, an immunoglobulin heavy chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding CDR3 of the immunoglobulin kappa light chain, a sequence encoding CDR3 of immunoglobulin lambda light chain, a sequence encoding CDR3 of the immunoglobulin heavy chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain, a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain, a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin heavy chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding a full-length variable domain of the immunoglobulin kappa light chain, a sequence encoding a full-length variable domain of the immunoglobulin lambda light chain, a sequence encoding a full-length variable domain of the immunoglobulin heavy chain, and combinations thereof.
In some embodiments, step (b) includes the capture probe using the nucleic acid encoding the immune cell receptor as a template, thereby generating an extended capture probe. In some embodiments, step (b) includes extending a 3′ end of the capture probe.
In some embodiments, step (b) includes generating a second strand of nucleic acid that includes (i) a sequence that is complementary to all or a portion of the spatial barcode, and (ii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
In some embodiments, the capture probe includes a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof. In some embodiments, the capture probe includes a functional domain.
In some embodiments, step (b) includes generating a second strand of nucleic acid that includes (i) a sequence that is complementary to all or a portion of the functional domain, (ii) a sequence that is complementary to all or a portion of the spatial barcode, and (iii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
In some embodiments, the method includes enriching the nucleic acid encoding the immune cell receptor of the immune cell clonotype.
In some embodiments, enriching includes hybridizing a plurality of hybridization probes to the nucleic acid encoding the immune cell receptor of the immune cell clonotype, where a hybridization probe includes (i) a sequence complementary to a portion of the nucleic acid encoding the immune cell receptor and (ii) a binding moiety that interacts with a capture moiety.
In some embodiments, the binding moiety includes biotin and the capture moiety includes streptavidin.
In some embodiments, enriching the nucleic acid encoding the immune cell receptor of the immune cell clonotype includes one or more blocking probes. In some embodiments, the one or more blocking probes includes a sequence having at least 80% identity to SEQ ID NO: 639. In some embodiments, the one or more blocking probes includes a sequence having at least 80% identity to SEQ ID NO: 640.
In some embodiments, the method includes amplifying the nucleic acid encoding the immune cell receptor of the immune cell clonotype, or a complement thereof, using (i) a first primer including all or a portion of the functional domain, where the functional domain is 5′ to the spatial barcode, and (ii) a second primer including a sequence that is substantially complementary to a portion of a sequence encoding a variable region of the immune cell receptor.
In some embodiments, the method includes amplifying the nucleic acid encoding the immune cell receptor of the immune cell clonotype, or a complement thereof, using (i) the first primer including all or a portion of the functional domain, where the functional domain is 5′ to the spatial barcode, and (ii) a third primer including a sequence that is substantially complementary to a portion of the nucleic acid sequence encoding a variable region of the immune cell receptor, where the third primer is 5′ to the second primer.
In some embodiments, the biological sample includes a tissue sample. In some embodiments, the tissue sample is a tissue section. In some embodiments, the tissue section is a fixed tissue section. In some embodiments, the fixed tissue section is a formalin-fixed paraffin-embedded tissue section. In some embodiments, the tissue section includes a tumor region.
In some embodiments, the nucleic acid encoding the immune cell receptor includes RNA. In some embodiments, the RNA is mRNA. In some embodiments, the nucleic acid encoding the immune cell receptor includes DNA. In some embodiments, the DNA is genomic DNA.
In some embodiments, the method includes imaging the biological sample.
In some embodiments, the determining in step (b) includes sequencing (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof.
In some embodiments, step (b) includes determining the presence of the immune cell clonotype at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of the immune cell clonotype at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of the immune cell clonotype at a location in the biological sample. In some embodiments, step (b) includes determining the presence of two or more immune cell clonotypes at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of two or more immune cell clonotypes at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of two or more immune cell clonotypes at a location in the biological sample. In some embodiments, the method includes comparing the two or more immune cell clonotypes. In some embodiments, the two or more immune cell clonotypes are each a B cell clonotype.
In some embodiments, the two or more immune cell clonotypes are each a T cell clonotype. In some embodiments, the two or more immune cell clonotypes comprise at least one T cell clonotype and at least one B cell clonotype.
Also provided herein are methods for determining the presence and/or abundance of an immune cell receptor at a location in a biological sample, the method including: (a) contacting a biological sample with an array including a plurality of capture probes, where a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that specifically binds to a nucleic acid encoding an immune cell receptor; and (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell receptor at a location in the biological sample.
In some embodiments, the immune cell receptor is a T cell receptor alpha chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the T cell receptor alpha chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor alpha chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the T cell receptor alpha chain. In some embodiments, the immune cell receptor is a T cell receptor beta chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the T cell receptor beta chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor beta chain. In some embodiments, step (b) includes determining a full-length variable domain of the T cell receptor beta chain. In some embodiments, the immune cell receptor is an immunoglobulin kappa light chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the immunoglobulin kappa light chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the immunoglobulin kappa light chain. In some embodiments, the immune cell receptor is an immunoglobulin lambda light chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the immunoglobulin lambda light chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the immunoglobulin lambda light chain. In some embodiments, the immune cell receptor is an immunoglobulin heavy chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain. In some embodiments, step (b) includes determining a sequence encoding CDR3 of the immunoglobulin heavy chain. In some embodiments, step (b) includes determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin heavy chain. In some embodiments, step (b) includes determining a sequence encoding a full-length variable domain of the immunoglobulin heavy chain.
In some embodiments, the capture domain binds a poly(A) sequence of a nucleic acid encoding an immune cell receptor. In some embodiments, the immune cell receptor is a T cell receptor alpha chain, a T cell receptor beta chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding CDR3 of the T cell receptor alpha chain, a sequence encoding CDR3 of the T cell receptor beta chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor alpha chain, a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor beta chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding a full-length variable domain of the T cell receptor alpha chain, a sequence encoding a full-length variable domain of the T cell receptor beta chain, and combinations thereof.
In some embodiments, the immune cell receptor is a B cell receptor an immunoglobulin kappa light chain, an immunoglobulin lambda light chain, an immunoglobulin heavy chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding CDR3 of the immunoglobulin kappa light chain, a sequence encoding CDR3 of immunoglobulin lambda light chain, a sequence encoding CDR3 of the immunoglobulin heavy chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain, a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain, a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin heavy chain, and combinations thereof. In some embodiments, step (b) includes determining: a sequence encoding a full-length variable domain of the immunoglobulin kappa light chain, a sequence encoding a full-length variable domain of the immunoglobulin lambda light chain, a sequence encoding a full-length variable domain of the immunoglobulin heavy chain, and combinations thereof.
In some embodiments, step (b) includes extending an end of the capture probe using the nucleic acid encoding the immune cell receptor as a template, thereby generating an extended capture probe. In some embodiments, step (b) includes extending a 3′ end of the capture probe.
In some embodiments, step (b) includes generating a second strand of nucleic acid that includes (i) a sequence that is complementary to all or a portion of the spatial barcode, and (ii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
In some embodiments, the capture probe includes a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof. In some embodiments, the capture probe includes a functional domain.
In some embodiments, step (b) includes generating a second strand of nucleic acid that includes (i) a sequence that is complementary to all or a portion of the functional domain, (ii) a sequence that is complementary to all or a portion of the spatial barcode, and (iii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
In some embodiments, the method includes enriching the nucleic acid encoding the immune cell receptor. In some embodiments, enriching includes hybridizing a plurality of hybridization probes to the nucleic acid encoding the immune cell receptor, where a hybridization probe includes (i) a sequence complementary to a portion of the nucleic acid encoding the immune cell receptor and (ii) a binding moiety that interacts with a capture moiety. In some embodiments, the binding moiety includes biotin and the capture moiety includes streptavidin. In some embodiments, enriching the nucleic acid encoding the immune cell receptor of the immune cell receptor includes one or more blocking probes. In some embodiments, the one or more blocking probes includes a sequence having at least 80% identity to SEQ ID NO: 639. In some embodiments, the one or more blocking probes includes a sequence having at least 80% identity to SEQ ID NO: 640.
In some embodiments, the method includes amplifying the nucleic acid encoding an immune cell receptor, or a complement thereof, using (i) a first primer including all or a portion of the functional domain, where the functional domain is 5′ to the spatial barcode in the second strand of nucleic acid, and (ii) a second primer including a sequence that is substantially complementary to a portion of a sequence encoding a variable region of the immune cell receptor.
In some embodiments, the method includes amplifying the nucleic acid encoding the immune cell receptor, or a complement thereof, using (i) the first primer including all or a portion of the functional domain, where the functional domain is 5′ to the spatial barcode, and (ii) a third primer including a sequence that is substantially complementary to a portion of the nucleic acid sequence encoding a variable region of the immune cell receptor, where the third primer is 5′ to the second primer.
In some embodiments, the biological sample includes a tissue sample. In some embodiments, the tissue sample is a tissue section. In some embodiments, the tissue section is a fixed tissue section. In some embodiments, the fixed tissue section is a formalin-fixed paraffin-embedded tissue section. In some embodiments, the tissue section includes a tumor region.
In some embodiments, the nucleic acid encoding the immune cell receptor includes RNA. In some embodiments, the RNA is mRNA. In some embodiments, the nucleic acid encoding the immune cell receptor includes DNA. In some embodiments, the DNA is genomic DNA.
In some embodiments, the method includes, prior to step (b), contacting the biological sample with ribosomal RNA depletion probes and mitochondrial RNA depletion probes.
In some embodiments, the method includes imaging the biological sample.
In some embodiments, the determining in step (b) includes sequencing (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof.
In some embodiments, step (b) includes determining the presence of the immune cell receptor at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of the immune cell receptor at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of the immune cell receptor at a location in the biological sample. In some embodiments, step (b) includes determining the presence of two or more immune cell receptors at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of two or more immune cell receptors at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of two or more immune cell receptors at a location in the biological sample. In some embodiments, the method includes comparing the two or more immune cell receptors. In some embodiments, the two or more immune cell clonotypes are each an immune cell receptor of a B cell. In some embodiments, the two or more immune cell clonotypes are each an immune cell receptor of a T cell. In some embodiments, the two or more immune cell clonotypes comprise at least one immune cell receptor of a T cell and at least one immune cell receptor from a B cell.
Also provided herein are arrays including a plurality of capture probes, where a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that binds to a nucleic acid encoding an immune cell receptor of an immune cell clonotype.
In some embodiments, the immune cell clonotype is a T cell clonotype. In some embodiments, the immune cell receptor is a T cell receptor alpha chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain. In some embodiments, the immune cell receptor is a T cell receptor beta chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain.
In some embodiments, the immune cell clonotype is a B cell clonotype. In some embodiments, the immune cell receptor is an immunoglobulin kappa light chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain. In some embodiments, the immune cell receptor is an immunoglobulin lambda light chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain. In some embodiments, the immune cell receptor is an immunoglobulin heavy chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain.
In some embodiments, the capture probe includes a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof.
Also provided herein are kits any one of the arrays described herein; one or more hybridization probes, where a hybridization probe includes (i) a sequence substantially complementary to a nucleic acid encoding an immune cell receptor and (ii) a binding moiety that interacts with a capturing moiety; and one or more blocking probes.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, patent application, or item of information was specifically and individually indicated to be incorporated by reference. To the extent publications, patents, patent applications, and items of information incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
Where values are described in terms of ranges, it should be understood that the description includes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated.
The term “each,” when used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection, unless expressly stated otherwise, or unless the context of the usage clearly indicates otherwise.
Various embodiments of the features of this disclosure are described herein. However, it should be understood that such embodiments are provided merely by way of example, and numerous variations, changes, and substitutions can occur to those skilled in the art without departing from the scope of this disclosure. It should also be understood that various alternatives to the specific embodiments described herein are also within the scope of this disclosure.
The following drawings illustrate certain embodiments of the features and advantages of this disclosure. These embodiments are not intended to limit the scope of the appended claims in any manner. Like reference symbols in the drawings indicate like elements.
A fundamental understanding of spatial heterogeneity with respect to T-cell receptor (TCR) and B-cell receptor (BCR) clonotypes within a biological sample is needed to understand which cells a TCR or BCR may be interacting with, the identity of TCR and/or BCR clonotypes in a given biological sample, or the identity of TCR and/or BCR clonotypes that are autoreactive in different autoimmune disorders. Numerous single-cell sequencing approaches can identify TCR and BCR clonotypes from a biological sample, however, at present methods are need to link TCR and BCR sequences to spatial locations within a biological sample. Additionally, identifying the clonal regions, that is, regions defined by the places where variable (V), diverse (D), and joining (J) segments join to from the complementarity determining regions, including CDR1, CDR2, and CDR3, which provide specificity to the TCRs and/or BCRs, is needed to help determine biological interactions. By coupling clonal information to spatial information it is possible to understand which T-cell and B-cell clonotypes may be specifically interacting with given cell types within a biological sample.
Provided herein are methods for determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample. Some embodiments of any of the methods described herein include capturing transcripts to identify an immune cell clonotype. Some embodiments of any of the methods herein include generating a nucleic acid library from captured transcripts. Some embodiments of any of the methods described herein include enriching analytes of interest in the nucleic acid library, including analytes to identify an immune cell clonotype.
Provided herein are methods for determining the presence and/or abundance of an immune cell receptor at a location in a biological sample. Some embodiments of any of the methods described herein include capturing analytes to identify an immune cell receptor. Some embodiments of any of the methods described herein include generating a nucleic acid library from captured analytes. Some embodiments of any of the methods described here include enriching analytes of interest in the nucleic acid library, including analytes to identify an immune cell receptor.
Spatial analysis methodologies and compositions described herein can provide a vast amount of analyte and/or expression data for a variety of analytes within a biological sample at high spatial resolution, while retaining native spatial context. Spatial analysis methods and compositions can include, e.g., the use of a capture probe including a spatial barcode (e.g., a nucleic acid sequence that provides information as to the location or position of an analyte within a cell or a tissue sample (e.g., mammalian cell or a mammalian tissue sample) and a capture domain that is capable of binding to an analyte (e.g., a protein and/or a nucleic acid) produced by and/or present in a cell. Spatial analysis methods and compositions can also include the use of a capture probe having a capture domain that captures an intermediate agent for indirect detection of an analyte. For example, the intermediate agent can include a nucleic acid sequence (e.g., a barcode) associated with the intermediate agent. Detection of the intermediate agent is therefore indicative of the analyte in the cell or tissue sample.
Non-limiting aspects of spatial analysis methodologies and compositions are described in U.S. Pat. Nos. 10,774,374, 10,724,078, 10,480,022, 10,059,990, 10,041,949, 10,002,316, 9,879,313, 9,783,841, 9,727,810, 9,593,365, 8,951,726, 8,604,182, 7,709,198, U.S. Patent Application Publication Nos. 2020/239946, 2020/080136, 2020/0277663, 2020/024641, 2019/330617, 2019/264268, 2020/256867, 2020/224244, 2019/194709, 2019/161796, 2019/085383, 2019/055594, 2018/216161, 2018/051322, 2018/0245142, 2017/241911, 2017/089811, 2017/067096, 2017/029875, 2017/0016053, 2016/108458, 2015/000854, 2013/171621, WO 2018/091676, WO 2020/176788, Rodriques et al., Science 363(6434): 1463-1467, 2019; Lee et al., Nat. Protoc. 10(3):442-458, 2015; Trejo et al., PLOS ONE 14(2):e0212031, 2019; Chen et al., Science 348(6233): aaa6090, 2015; Gao et al., BMC Biol. 15:50, 2017; and Gupta et al., Nature Biotechnol. 36:1197-1202, 2018; the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev C, dated June 2020), and/or the Visium Spatial Tissue Optimization Reagent Kits User Guide (e.g., Rev C, dated July 2020), both of which are available at the 10× Genomics® (sequencing technology) Support Documentation website, and can be used herein in any combination. Further non-limiting aspects of spatial analysis methodologies and compositions are described herein.
Some general terminology that may be used in this disclosure can be found in Section (I)(b) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Typically, a “barcode” is a label, or identifier, that conveys or is capable of conveying information (e.g., information about an analyte in a sample, a bead, and/or a capture probe). A barcode can be part of an analyte, or independent of an analyte. A barcode can be attached to an analyte. A particular barcode can be unique relative to other barcodes. For the purpose of this disclosure, an “analyte” can include any biological substance, structure, moiety, or component to be analyzed. The term “target” can similarly refer to an analyte of interest.
In some embodiments, the analyte is an immune cell receptor. In some embodiments, the immune cell receptor is a B cell receptor. In some embodiments, the B cell receptor is an immunoglobulin kappa light chain. In some embodiments, the variable region of the analyte includes a CDR3 region of the immunoglobulin kappa light chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the immunoglobulin kappa light chain.
In some embodiments, the B cell receptor is an immunoglobulin lambda light chain. In some embodiments, the variable region of the analyte includes a CDR3 of the immunoglobulin lambda light chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the immunoglobulin lambda light chain.
In some embodiments, the B cell receptor is an immunoglobulin heavy chain. In some embodiments, the variable region of the analyte includes a CDR3 of the immunoglobulin heavy chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the immunoglobulin heavy chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the immunoglobulin heavy chain.
In some embodiments, the immune cell receptor is a T cell receptor. In some embodiments, the T cell receptor is a T cell receptor alpha chain. In some embodiments, the variable region of the analyte includes a CDR3 of the T cell receptor alpha chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the T cell receptor alpha chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the T cell receptor alpha chain.
In some embodiments, the T cell receptor is a T cell receptor beta chain. In some embodiments, the variable region of the analyte includes a CDR3 of the T cell receptor beta chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the T cell receptor beta chain. In some embodiments, the variable region of the analyte further includes a full-length variable domain of the T cell receptor beta chain.
Analytes can be broadly classified into one of two groups: nucleic acid analytes, and non-nucleic acid analytes. Examples of non-nucleic acid analytes include, but are not limited to, lipids, carbohydrates, peptides, proteins, glycoproteins (N-linked or O-linked), lipoproteins, phosphoproteins, specific phosphorylated or acetylated variants of proteins, amidation variants of proteins, hydroxylation variants of proteins, methylation variants of proteins, ubiquitylation variants of proteins, sulfation variants of proteins, viral proteins (e.g., viral capsid, viral envelope, viral coat, viral accessory, viral glycoproteins, viral spike, etc.), extracellular and intracellular proteins, antibodies, and antigen binding fragments. In some embodiments, the analyte(s) can be localized to subcellular location(s), including, for example, organelles, e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc. In some embodiments, analyte(s) can be peptides or proteins, including without limitation antibodies and enzymes. Additional examples of analytes can be found in Section (I)(c) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. In some embodiments, an analyte can be detected indirectly, such as through detection of an intermediate agent, for example, a ligation product or an analyte capture agent (e.g., an oligonucleotide-conjugated antibody), such as those described herein.
A “biological sample” is typically obtained from the subject for analysis using any of a variety of techniques including, but not limited to, biopsy, surgery, and laser capture microscopy (LCM), and generally includes cells and/or other biological material from the subject. In some embodiments, a biological sample can be a tissue section. In some embodiments, a biological sample can be a fixed and/or stained biological sample (e.g., a fixed and/or stained tissue section). Non-limiting examples of stains include histological stains (e.g., hematoxylin and/or eosin) and immunological stains (e.g., fluorescent stains). In some embodiments, a biological sample (e.g., a fixed and/or stained biological sample) can be imaged. Biological samples are also described in Section (I)(d) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
In some embodiments, a biological sample is permeabilized with one or more permeabilization reagents. For example, permeabilization of a biological sample can facilitate analyte capture. Exemplary permeabilization agents and conditions are described in Section (I)(d)(ii)(13) or the Exemplary Embodiments Section of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
Array-based spatial analysis methods involve the transfer of one or more analytes from a biological sample to an array of features on a substrate, where each feature is associated with a unique spatial location on the array. Subsequent analysis of the transferred analytes includes determining the identity of the analytes and the spatial location of the analytes within the biological sample. The spatial location of an analyte within the biological sample is determined based on the feature to which the analyte is bound (e.g., directly or indirectly) on the array, and the feature's relative spatial location within the array.
A “capture probe” refers to any molecule capable of capturing (directly or indirectly) and/or labelling an analyte (e.g., an analyte of interest) in a biological sample. In some embodiments, the capture probe is a nucleic acid or a polypeptide. In some embodiments, the capture probe includes a barcode (e.g., a spatial barcode and/or a unique molecular identifier (UMI)) and a capture domain). In some embodiments, a capture probe can include a cleavage domain and/or a functional domain (e.g., a primer-binding site, such as for next-generation sequencing (NGS)). See, e.g., Section (II)(b) (e.g., subsections (i)-(vi)) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Generation of capture probes can be achieved by any appropriate method, including those described in Section (II)(d)(ii) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
In some embodiments, more than one analyte type (e.g., nucleic acids and proteins) from a biological sample can be detected (e.g., simultaneously or sequentially) using any appropriate multiplexing technique, such as those described in Section (IV) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
In some embodiments, detection of one or more analytes (e.g., protein analytes) can be performed using one or more analyte capture agents. As used herein, an “analyte capture agent” refers to an agent that interacts with an analyte (e.g., an analyte in a biological sample) and with a capture probe (e.g., a capture probe attached to a substrate or a feature) to identify the analyte. In some embodiments, the analyte capture agent includes: (i) an analyte binding moiety (e.g., that binds to an analyte), for example, an antibody or antigen-binding fragment thereof; (ii) analyte binding moiety barcode; and (iii) an analyte capture sequence. As used herein, the term “analyte binding moiety barcode” refers to a barcode that is associated with or otherwise identifies the analyte binding moiety. As used herein, the term “analyte capture sequence” refers to a region or moiety configured to hybridize to, bind to, couple to, or otherwise interact with a capture domain of a capture probe. In some cases, an analyte binding moiety barcode (or portion thereof) may be able to be removed (e.g., cleaved) from the analyte capture agent. Additional description of analyte capture agents can be found in Section (II)(b)(ix) of WO 2020/176788 and/or Section (II)(b)(viii) U.S. Patent Application Publication No. 2020/0277663.
There are at least two methods to associate a spatial barcode with one or more neighboring cells, such that the spatial barcode identifies the one or more cells, and/or contents of the one or more cells, as associated with a particular spatial location. One method is to promote analytes or analyte proxies (e.g., intermediate agents) out of a cell and towards a spatially-barcoded array (e.g., including spatially-barcoded capture probes). Another method is to cleave spatially-barcoded capture probes from an array and promote the spatially-barcoded capture probes towards and/or into or onto the biological sample.
The functional sequences can generally be selected for compatibility with any of a variety of different sequencing systems, e.g., Ion Torrent Proton or PGM, ILLUMINA® (sequencing technology) sequencing instruments, PacBio, Oxford Nanopore, etc., and the requirements thereof. In some embodiments, functional sequences can be selected for compatibility with non-commercialized sequencing systems. Examples of such sequencing systems and techniques, for which suitable functional sequences can be used, include (but are not limited to) Ion Torrent Proton or PGM sequencing, ILLUMINA® (sequencing technology) sequencing, PacBio SMRT sequencing, and Oxford Nanopore sequencing. Further, in some embodiments, functional sequences can be selected for compatibility with other sequencing systems, including non-commercialized sequencing systems.
In some embodiments, the spatial barcode 105 and functional sequences 104 is common to all of the probes attached to a given feature. In some embodiments, the UMI sequence 106 of a capture probe attached to a given feature is different from the UMI sequence of a different capture probe attached to the given feature.
In some cases, capture probes may be configured to prime, replicate, and consequently yield optionally barcoded extension products from a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g., a ligation product or an analyte capture agent), or a portion thereof), or derivatives thereof (see, e.g., Section (II)(b)(vii) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663 regarding extended capture probes). In some cases, capture probes may be configured to form ligation products with a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent, or portion thereof), thereby creating ligations products that serve as proxies for a template.
As used herein, an “extended capture probe” refers to a capture probe having additional nucleotides added to the terminus (e.g., 3′ or 5′ end) of the capture probe thereby extending the overall length of the capture probe. For example, an “extended 3′ end” indicates additional nucleotides were added to the most 3′ nucleotide of the capture probe to extend the length of the capture probe, for example, by polymerization reactions used to extend nucleic acid molecules including templated polymerization catalyzed by a polymerase (e.g., a DNA polymerase or a reverse transcriptase). In some embodiments, extending the capture probe includes adding to a 3′ end of a capture probe a nucleic acid sequence that is complementary to a nucleic acid sequence of an analyte or intermediate agent specifically bound to the capture domain of the capture probe. In some embodiments, the capture probe is extended using reverse transcription. In some embodiments, the capture probe is extended using one or more DNA polymerases. The extended capture probes include the sequence of the capture probe and the sequence of the spatial barcode of the capture probe.
In some embodiments, extended capture probes are amplified (e.g., in bulk solution or on the array) to yield quantities that are sufficient for downstream analysis, e.g., via DNA sequencing. In some embodiments, extended capture probes (e.g., DNA molecules) act as templates for an amplification reaction (e.g., a polymerase chain reaction).
Additional variants of spatial analysis methods, including in some embodiments, an imaging step, are described in Section (II)(a) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Analysis of captured analytes (and/or intermediate agents or portions thereof), for example, including sample removal, extension of capture probes, sequencing (e.g., of a cleaved extended capture probe and/or a cDNA molecule complementary to an extended capture probe), sequencing on the array (e.g., using, for example, in situ hybridization or in situ ligation approaches), temporal analysis, and/or proximity capture, is described in Section (II)(g) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Some quality control measures are described in Section (II)(h) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
Spatial information can provide information of biological and/or medical importance. For example, the methods and compositions described herein can allow for: identification of one or more biomarkers (e.g., diagnostic, prognostic, and/or for determination of efficacy of a treatment) of a disease or disorder; identification of a candidate drug target for treatment of a disease or disorder; identification (e.g., diagnosis) of a subject as having a disease or disorder; identification of stage and/or prognosis of a disease or disorder in a subject; identification of a subject as having an increased likelihood of developing a disease or disorder; monitoring of progression of a disease or disorder in a subject; determination of efficacy of a treatment of a disease or disorder in a subject; identification of a patient subpopulation for which a treatment is effective for a disease or disorder; modification of a treatment of a subject with a disease or disorder; selection of a subject for participation in a clinical trial; and/or selection of a treatment for a subject with a disease or disorder.
Spatial information can provide information of biological importance. For example, the methods and compositions described herein can allow for: identification of transcriptome and/or proteome expression profiles (e.g., in healthy and/or diseased tissue); identification of multiple analyte types in close proximity (e.g., nearest neighbor analysis); determination of up- and/or down-regulated genes and/or proteins in diseased tissue; characterization of tumor microenvironments; characterization of tumor immune responses; characterization of cells types and their co-localization in tissue; and identification of genetic variants within tissues (e.g., based on gene and/or protein expression profiles associated with specific disease or disorder biomarkers).
Typically, for spatial array-based methods, a substrate functions as a support for direct or indirect attachment of capture probes to features of the array. A “feature” is an entity that acts as a support or repository for various molecular entities used in spatial analysis. In some embodiments, some or all of the features in an array are functionalized for analyte capture. Exemplary substrates are described in Section (II)(c) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Exemplary features and geometric attributes of an array can be found in Sections (II)(d)(i), (II)(d)(iii), and (II)(d)(iv) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
Generally, analytes and/or intermediate agents (or portions thereof) can be captured when contacting a biological sample with a substrate including capture probes (e.g., a substrate with capture probes embedded, spotted, printed, fabricated on the substrate, or a substrate with features (e.g., beads, wells) comprising capture probes). As used herein, “contact,” “contacted,” and/or “contacting,” a biological sample with a substrate refers to any contact (e.g., direct or indirect) such that capture probes can interact (e.g., bind covalently or non-covalently (e.g., hybridize)) with analytes from the biological sample. Capture can be achieved actively (e.g., using electrophoresis) or passively (e.g., using diffusion). Analyte capture is further described in Section (II)(e) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
In some cases, spatial analysis can be performed by attaching and/or introducing a molecule (e.g., a peptide, a lipid, or a nucleic acid molecule) having a barcode (e.g., a spatial barcode) to a biological sample (e.g., to a cell in a biological sample). In some embodiments, a plurality of molecules (e.g., a plurality of nucleic acid molecules) having a plurality of barcodes (e.g., a plurality of spatial barcodes) are introduced to a biological sample (e.g., to a plurality of cells in a biological sample) for use in spatial analysis. In some embodiments, after attaching and/or introducing a molecule having a barcode to a biological sample, the biological sample can be physically separated (e.g., dissociated) into single cells or cell groups for analysis. Some such methods of spatial analysis are described in Section (III) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
In some cases, spatial analysis can be performed by detecting multiple oligonucleotides that hybridize to an analyte. In some instances, for example, spatial analysis can be performed using RNA-templated ligation (RTL). Methods of RTL have been described previously. See, e.g., Credle et al., Nucleic Acids Res. 2017 Aug. 21; 45(14):e128. Typically, RTL includes hybridization of two oligonucleotides to adjacent sequences on an analyte (e.g., an RNA molecule, such as an mRNA molecule). In some instances, the oligonucleotides are DNA molecules. In some instances, one of the oligonucleotides includes at least two ribonucleic acid bases at the 3′ end and/or the other oligonucleotide includes a phosphorylated nucleotide at the 5′ end. In some instances, one of the two oligonucleotides includes a capture domain (e.g., a poly(A) sequence, a non-homopolymeric sequence). After hybridization to the analyte, a ligase (e.g., SplintR ligase) ligates the two oligonucleotides together, creating a ligation product. In some instances, the two oligonucleotides hybridize to sequences that are not adjacent to one another. For example, hybridization of the two oligonucleotides creates a gap between the hybridized oligonucleotides. In some instances, a polymerase (e.g., a DNA polymerase) can extend one of the oligonucleotides prior to ligation. After ligation, the ligation product is released from the analyte. In some instances, the ligation product is released using an endonuclease (e.g., RNAse H). The released ligation product can then be captured by capture probes (e.g., instead of direct capture of an analyte) on an array, optionally amplified, and sequenced, thus determining the location and optionally the abundance of the analyte in the biological sample.
During analysis of spatial information, sequence information for a spatial barcode associated with an analyte is obtained, and the sequence information can be used to provide information about the spatial distribution of the analyte in the biological sample. Various methods can be used to obtain the spatial information. In some embodiments, specific capture probes and the analytes they capture are associated with specific locations in an array of features on a substrate. For example, specific spatial barcodes can be associated with specific array locations prior to array fabrication, and the sequences of the spatial barcodes can be stored (e.g., in a database) along with specific array location information, so that each spatial barcode uniquely maps to a particular array location.
Alternatively, specific spatial barcodes can be deposited at predetermined locations in an array of features during fabrication such that at each location, only one type of spatial barcode is present so that spatial barcodes are uniquely associated with a single feature of the array. Where necessary, the arrays can be decoded using any of the methods described herein so that spatial barcodes are uniquely associated with array feature locations, and this mapping can be stored as described above.
When sequence information is obtained for capture probes and/or analytes during analysis of spatial information, the locations of the capture probes and/or analytes can be determined by referring to the stored information that uniquely associates each spatial barcode with an array feature location. In this manner, specific capture probes and captured analytes are associated with specific locations in the array of features. Each array feature location represents a position relative to a coordinate reference point (e.g., an array location, a fiducial marker) for the array. Accordingly, each feature location has an “address” or location in the coordinate space of the array.
Some exemplary spatial analysis workflows are described in the Exemplary Embodiments section of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See, for example, the Exemplary embodiment starting with “In some non-limiting examples of the workflows described herein, the sample can be immersed . . . ” of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See also, e.g., the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev C, dated June 2020), and/or the Visium Spatial Tissue Optimization Reagent Kits User Guide (e.g., Rev C, dated July 2020).
In some embodiments, spatial analysis can be performed using dedicated hardware and/or software, such as any of the systems described in Sections (II)(e)(ii) and/or (V) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663, or any of one or more of the devices or methods described in Sections Control Slide for Imaging, Methods of Using Control Slides and Substrates for, Systems of Using Control Slides and Substrates for Imaging, and/or Sample and Array Alignment Devices and Methods, Informational labels of WO 2020/123320.
Suitable systems for performing spatial analysis can include components such as a chamber (e.g., a flow cell or sealable, fluid-tight chamber) for containing a biological sample. The biological sample can be mounted for example, in a biological sample holder. One or more fluid chambers can be connected to the chamber and/or the sample holder via fluid conduits, and fluids can be delivered into the chamber and/or sample holder via fluidic pumps, vacuum sources, or other devices coupled to the fluid conduits that create a pressure gradient to drive fluid flow. One or more valves can also be connected to fluid conduits to regulate the flow of reagents from reservoirs to the chamber and/or sample holder.
The systems can optionally include a control unit that includes one or more electronic processors, an input interface, an output interface (such as a display), and a storage unit (e.g., a solid state storage medium such as, but not limited to, a magnetic, optical, or other solid state, persistent, writeable and/or re-writeable storage medium). The control unit can optionally be connected to one or more remote devices via a network. The control unit (and components thereof) can generally perform any of the steps and functions described herein. Where the system is connected to a remote device, the remote device (or devices) can perform any of the steps or features described herein. The systems can optionally include one or more detectors (e.g., CCD, CMOS) used to capture images. The systems can also optionally include one or more light sources (e.g., LED-based, diode-based, lasers) for illuminating a sample, a substrate with features, analytes from a biological sample captured on a substrate, and various control and calibration media.
The systems can optionally include software instructions encoded and/or implemented in one or more of tangible storage media and hardware components such as application specific integrated circuits. The software instructions, when executed by a control unit (and in particular, an electronic processor) or an integrated circuit, can cause the control unit, integrated circuit, or other component executing the software instructions to perform any of the method steps or functions described herein.
In some cases, the systems described herein can detect (e.g., register an image) the biological sample on the array. Exemplary methods to detect the biological sample on an array are described in PCT Application No. 2020/061064 and/or U.S. patent application Ser. No. 16/951,854.
Prior to transferring analytes from the biological sample to the array of features on the substrate, the biological sample can be aligned with the array. Alignment of a biological sample and an array of features including capture probes can facilitate spatial analysis, which can be used to detect differences in analyte presence and/or level within different positions in the biological sample, for example, to generate a three-dimensional map of the analyte presence and/or level. Exemplary methods to generate a two-and/or three-dimensional map of the analyte presence and/or level are described in PCT Application No. 2020/053655 and spatial analysis methods are generally described in WO 2020/061108 and/or U.S. patent application Ser. No. 16/951,864.
In some cases, a map of analyte presence and/or level can be aligned to an image of a biological sample using one or more fiducial markers, e.g., objects placed in the field of view of an imaging system which appear in the image produced, as described in the Substrate Attributes Section, Control Slide for Imaging Section of WO 2020/123320, PCT Application No. 2020/061066, and/or U.S. patent application Ser. No. 16/951,843. Fiducial markers can be used as a point of reference or measurement scale for alignment (e.g., to align a sample and an array, to align two substrates, to determine a location of a sample or array on a substrate relative to a fiducial marker) and/or for quantitative measurements of sizes and/or distances.
Spatial Transcriptomics for Antigen Receptors
A fundamental understanding of spatial heterogeneity with respect to T-cell receptor (TCR) and B-cell receptor (BCR) clonotypes within a biological sample is needed to understand multiple facets of their functionality, including, for example, which cells a particular TCR or BCR may be interacting with within the biological sample, the identity of TCR and/or BCR clonotypes in a given biological sample, and/or the identity of TCR and/or BCR clonotypes that are autoreactive in different autoimmune disorders. Numerous single-cell sequencing approaches can identify TCR and BCR clonotypes from a biological sample, however, at present methods are needed to link TCR and BCR sequences to spatial locations within a biological sample. Additionally, identifying the clonal regions, that is, regions defined by the places where variable (V), diverse (D), and joining (J) segments join to form the complementarity determining regions, including CDR1, CDR2, and CDR3, which provide specificity to the TCRs and/or BCRs, would greatly benefit the scientific arts. By coupling clonal information to spatial information it is possible to understand which T-cell and B-cell clonotypes may be specifically interacting with given cell types within a biological sample.
However, capturing analytes encoding immune cell receptors can provide unique challenges. For example, spatially capturing the TCR and BCR gene components with sufficient efficiency to profile the majority of clonotypes in a given tissue is difficult. Capturing analytes encoding immune cell receptors with conventional short-read sequencing methods can result in a loss of sequenced regions that are more than about 1 kb away from the point where sequencing starts. Linking separate TCR or BCR gene components that together form a complete receptor using sequencing data from spots containing multiple different cells are challenges addressed by the methods described herein.
Methods described herein are utilized to analyze the various sequences of TCRs and BCRs from immune cells, for example, various clonotypes. In some embodiments, the methods are used to analyze the sequence of a TCR alpha chain, a TCR beta chain, a TCR delta chain, a TCR gamma chain, or any fragment thereof (e.g., variable regions including V(D)J or VJ regions, constant regions, transmembrane regions, fragments thereof, combinations thereof, and combinations of fragments thereof). In some embodiments, the methods described herein can be used to analyze the sequence of a B cell receptor heavy chain, B cell receptor light chain, or any fragment thereof (e.g., variable regions including V(D)J or VJ regions, constant regions, transmembrane regions, fragments thereof, combinations thereof, and combinations of fragments thereof).
Analytes
The analyte sequences present in the nucleic acid library (e.g., nucleic acid library generated from single-cells or from a biological sample on an array) can be captured from a biological sample (e.g., any of the biological samples described herein). In some embodiments, the biological sample is a tissue sample. In some embodiments, the tissue sample is a tissue section. In some embodiments, the tissue section is a fixed tissue section. In some embodiments, the fixed tissue section is formalin-fixed paraffin-embedded tissue section. In some embodiments, the tissue section is a fresh, frozen tissue section.
The analytes to be detected can be any of the analytes described herein. Analytes can include a nucleic acid molecule with a nucleic acid sequence encoding at least a portion of a V(D)J sequence of an immune cell receptor (e.g., a TCR or BCR). In some embodiments, the analyte is RNA. In some embodiments, the RNA is mRNA. In some embodiments, the analyte is DNA. In some embodiments, the DNA is genomic DNA. In some embodiments, the analytes are analytes encoding immune cell receptors. In some embodiments, analytes encoding immune cell receptors identify clonotype populations from a biological sample.
In some embodiments, analytes include a constant region, such as a constant region present in analytes encoding immune cell receptors. In some embodiments, analytes include a variable region, such as analytes encoding immune cell receptors. In some embodiments, analytes encoding immune cell receptors identify clonotype populations present in a biological sample.
In some embodiments, the analyte is an immune cell receptor. In some embodiments, the immune cell receptor is a B cell receptor. In some embodiments, the B cell receptor is an immunoglobulin kappa light chain. In some embodiments, the variable region of the analyte includes a CDR3 region of the immunoglobulin kappa light chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the immunoglobulin kappa light chain.
In some embodiments, the B cell receptor is an immunoglobulin lambda light chain. In some embodiments, the variable region of the analyte includes a CDR3 of the immunoglobulin lambda light chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the immunoglobulin lambda light chain.
In some embodiments, the B cell receptor is an immunoglobulin heavy chain. In some embodiments, the variable region of the analyte includes a CDR3 of the immunoglobulin heavy chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the immunoglobulin heavy chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the immunoglobulin heavy chain.
In some embodiments, the immune cell receptor is a T cell receptor. In some embodiments, the T cell receptor is a T cell receptor alpha chain. In some embodiments, the variable region of the analyte includes a CDR3 of the T cell receptor alpha chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the T cell receptor alpha chain. In some embodiments, the variable region of the analyte includes a full-length variable domain of the T cell receptor alpha chain.
In some embodiments, the T cell receptor is a T cell receptor beta chain. In some embodiments, the variable region of the analyte includes a CDR3 of the T cell receptor beta chain. In some embodiments, the variable region of the analyte includes one or both of CDR1 and CDR2 of the T cell receptor beta chain. In some embodiments, the variable region of the analyte further includes a full-length variable domain of the T cell receptor beta chain.
Capturing Analytes Encoding Immune Cell Receptors
Provided herein are methods for determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample, the method including (a) contacting a biological sample with an array including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that specifically binds to a nucleic acid encoding an immune cell receptor of the immune cell clonotype, and, (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell clonotype at a location in the biological sample.
Also provided herein are methods for determining the presence and/or abundance of an immune cell receptor at a location in a biological sample, the method including (a) contacting a biological sample with an array including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that specifically binds to a nucleic acid encoding an immune cell receptor; and (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell receptor at a location in the biological sample.
Also provided herein are methods for determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample, the method including (a) contacting a biological sample with an array including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that binds to a nucleic acid encoding an immune cell receptor of the immune cell clonotype; (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell clonotype at a location in the biological sample.
Also provided herein are methods for determining the presence and/or abundance of an immune cell receptor at a location in a biological sample, the method including (a) contacting a biological sample with an array including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that binds to a nucleic acid encoding an immune cell receptor and (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell receptor at a location in the biological sample.
In some embodiments of determining the presence and/or abundance of an immune cell clonotype or an immune cell receptor at a location in a biological sample, step (b) includes extending an end of the capture probe using the nucleic acid encoding the immune cell receptor as a template, thereby generating an extended capture probe. In some embodiments, extending an end of the capture probe includes using a reverse transcriptase (e.g., any of the reverse transcriptases described herein). In some embodiments, step (b) includes extending a 3′ end of the capture probe. In some embodiments, step (b) includes generating a second strand of nucleic acid that includes (i) a sequence that is complementary to all or a portion of the spatial barcode, and (ii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
In some embodiments of determining the presence and/or abundance of an immune cell clonotype or an immune cell receptor at a location in a biological sample, the capture probe includes a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof. In some embodiments, the capture probe includes a functional domain. In some embodiments, the capture domain includes a poly(T) sequence. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain. In some embodiments, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain. In some embodiments, the capture probe binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain.
Variable Region Primer Enrichment
As demonstrated in the Examples, analytes encoding immune cell receptors were captured and identified with capture domains designed to specifically bind a constant region of a particular immune cell receptor from a biological sample. However, such a strategy does not capture analytes other than analytes encoding immune cell receptors. An additional and alternative approach can include using one or more variable region (V-region) specific primer sets to amplify analytes encoding immune cell receptors (e.g., TCRs and/or BCRs) from nucleic acid libraries generated from poly(T) captured total cDNA libraries, thus allowing sequencing into CDR regions (e.g., CDR3 region) from the 5′ end of an amplicon. An advantage of this approach would be the simultaneous detection of lymphocyte clonality alongside global spatial gene expression. An additional consideration is capturing full IGH complexity (e.g., IGH isotypes, e.g., IGHA1-2, IGHG1-4, IGHM, IGHD, and IGHE) without paired end sequencing reads through the CDR3 region. Additional receptor diversity is added to the BCR throughout development and may be difficult to distinguish from sequencing errors with only a single CDR3 read. Additionally, some analytes encoding immune cell receptors are known to be in low abundance (See e.g., Tu, A. A., et al., TCR sequencing paired with massively parallel 3′ RNAseq reveals clonotypic T cell signatures, Nature Immunology, 20, 1692-1699 (2019); Singh M., et al., High-throughput long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes. Nature Communications, 10, 3120 (2019), both of which are incorporated herein by reference in their entireties). Thus, for example, variable region primer enrichment can provide an alternate method to enrich for analytes encoding immune cell receptors from arrays with capture probes including a poly(T) capture domain, followed by one or more amplification reactions (e.g., PCR).
In some embodiments of any of the spatial methods described herein, step (b) further includes generating a second strand of nucleic acid that includes (i) a sequence that is complementary to all or a portion of the functional domain, (ii) a sequence that is complementary to all or a portion of the spatial barcode, and (iii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor. In some embodiments, step (b) further includes amplifying the second strand of the nucleic acid using (i) a first primer including all or a portion of the functional domain, wherein the functional domain is 5′ to the spatial barcode in the second strand of nucleic acid, and (ii) a second primer including a sequence that is substantially complementary to a portion of a sequence encoding a variable region of the immune cell receptor.
In some embodiments, more than one second primer including a sequence substantially complementary to a portion of the sequence encoding the variable region of the immune cell receptor is used. For example, a nested PCR strategy can be used where a first amplification product is generated with a variable region primer and a primer substantially complementary to the functional domain 5′ to the spatial barcode, followed by a second, a third, or a fourth round of amplification using a second, a third, or a fourth variable region primer internal to the first region variable region primer (e.g., 5′ to the first variable region primer)(for example, see
Hybridization Probes and Blocking Probes
In some embodiments, targeted enrichment of cDNAs of interest are enriched from cDNA derived libraries generated from captured analytes (e.g., immune cell analytes). For example, a pool of hybridization probes to an analyte of interest, or a complement thereof, can be designed. In some embodiments, about 10 to about 500 hybridization probes, about 25 to about 450 hybridization probes, about 50 to about 400 hybridization probes, about 75 to about 350 hybridization probes, or about 100 to 300 hybridization probes can be designed for hybridizing to an analyte of interest, or a complement thereof. In some embodiments, the hybridization probes can include an additional moiety, such as a binding moiety, (e.g., biotin) capable of binding another moiety, such as a capture moiety, (e.g., streptavidin). Thus, in some embodiments, one or more hybridization probes (e.g., including an additional moiety, such as biotin) hybridize to the analyte of interest, or complement thereof, in the cDNA library and the total cDNA library is processed on streptavidin beads, for example. The biotin moieties of the hybridization probes specifically bind the streptavidin molecules, thereby enriching for the analytes of interest, or complements thereof. Hybridization probes can be designed to be complementary to any analyte or its complementary sequence, including, for example, analytes encoding immune cell analytes.
In some embodiments, enriching analytes of interest includes the use of blocking probes. Blocking probes can be added to the cDNA library before, after, or concurrently with hybridization probes. In some embodiments, blocking probes reduce background (e.g., non-specific binding events) when enriching for targets within the cDNA library. In some embodiments, blocking probes can be about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, or about 150 nucleotides long. In some embodiments, blocking probes are designed specifically to domains present in one or more members of the cDNA library. In some embodiments, one blocking probe is added to the cDNA library. In some embodiments, two or more blocking probes (e.g., different blocking probes). In some embodiments, 3, 4, 5 or more different blocking probes are added to the cDNA library (e.g., blocking probes having a different sequence). In some embodiments, the blocking probe comprises SEQ ID NO: 639. In some embodiments, the blocking probe comprises SEQ ID NO: 640. In some embodiments, the blocking probe comprises at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 639. In some embodiments, the blocking probe comprises at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 640.
Identifying Immune Cell Receptors
In some embodiments of determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample, determining in step (b) includes sequencing (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof. Any of the sequencing methods described herein can be used. In some embodiments, step (b) includes determining the presence of the immune cell clonotype at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of the immune cell clonotype at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of the immune cell clonotype at a location in the biological sample. In some embodiments, step (b) includes determining the presence of two or more immune cell clonotypes at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of two or more immune cell clonotypes at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of two or more immune cell clonotypes at a location in the biological sample. In some embodiments, the method includes comparing the two or more immune cell clonotypes. In some embodiments, the two or more immune cell clonotypes are each a B cell clonotype. In some embodiments, the two or more immune cell clonotypes are each a T cell clonotype. In some embodiments, the two or more immune cell clonotypes include at least one T cell clonotype and at least one B cell clonotype.
In some embodiments of determining the presence and/or abundance of an immune cell receptor at a location in a biological sample, the determining in step (b) includes sequencing (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof. In some embodiments, step (b) includes determining the presence of the immune cell receptor at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of the immune cell receptor at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of the immune cell receptor at a location in the biological sample. In some embodiments, step (b) includes determining the presence of two or more immune cell receptors at a location in the biological sample. In some embodiments, step (b) includes determining the abundance of two or more immune cell receptors at a location in the biological sample. In some embodiments, step (b) includes determining the presence and abundance of two or more immune cell receptors at a location in the biological sample. In some embodiments, the method includes comparing the two or more immune cell receptors. In some embodiments, the two or more immune cell clonotypes are each an immune cell receptor of a B cell. In some embodiments, two or more immune cell clonotypes are each an immune cell receptor of a T cell. In some embodiments, two or more immune cell clonotypes include at least one immune cell receptor of a T cell and at least one immune cell receptor from a B cell.
In some embodiments of determining the presence and/or abundance of an immune cell clonotype or an immune cell receptor at a location in a biological sample, includes prior to step (b), contacting the biological sample with ribosomal RNA depletion probes and/or mitochondrial RNA depletion probes. In some embodiments, the biological sample is imaged. In some embodiments, the biological sample is stained.
Arrays and Kits
Provided herein are arrays including a plurality of capture probes, where a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain that specifically binds to a nucleic acid encoding an immune cell receptor of an immune cell clonotype. In some arrays, the immune cell clonotype is a T cell clonotype. In some arrays, the immune cell receptor is a T cell receptor alpha chain. In some arrays, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain. In some arrays, the immune cell receptor is a T cell receptor beta chain. In some arrays, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain. In some arrays, the immune cell clonotype is a B cell clonotype. In some arrays, the immune cell receptor is an immunoglobulin kappa light chain. In some arrays, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain. In some arrays, the immune cell receptor is an immunoglobulin lambda light chain. In some arrays, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain. In some arrays, the immune cell receptor is an immunoglobulin heavy chain. In some arrays, the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain. In some arrays, the capture probe includes a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof.
Also provided herein are kits including an array (e.g., any of the arrays described herein) and one or more hybridization probes, wherein a hybridization probe includes (i) a sequence substantially complementary to a nucleic acid encoding an immune cell receptor and (ii) a binding moiety that interacts with a capturing moiety and one or more blocking probes.
Also provided herein are kits, including an array of any of the arrays described herein and one or both of ribosomal RNA depletion probes and mitochondrial RNA depletion probes.
Targeted RNA depletion allows for depletion or removal of one or more species of undesirable RNA molecules (e.g., ribosomal RNA and/or mitochondrial RNA), thereby reducing the pool and concentration of undesirable RNA molecules in the sample which could interfere with desired target detection (e.g., detection of mRNA). To achieve depletion, one or more probes are designed that hybridize to one or more undesirable RNA molecules. For example, in one embodiment, probes can be administered to a biological sample that selectively hybridize to ribosomal RNA (rRNA), thereby reducing the pool and concentration of rRNA in the sample. In one embodiment, probes can be administered to a biological sample that selectively hybridize to mitochondria RNA (mtRNA), thereby reducing the pool and concentration of mtRNA in the sample. Subsequent application of capture probes to the sample can result in improved capture of other types of RNA due to a reduction in undesirable RNA (e.g., down-selected RNA) present in the sample.
Upon depletion of the undesirable RNA, the sample will contain an enriched population of the RNA target of interest (e.g., an mRNA target). In some embodiments, the undesirable RNA comprises less than 20%, 19%, 18%, 17%, 16%15%, 14%, 13%, 12%, 11%10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or any range therein, of the total RNA in the sample after depletion of the undesirable RNA (i.e., less than 20%, 19%, 18%, 17%, 16%15%, 14%, 13%, 12%, 11%10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or any range therein compared to a sample that undergoes no depletion step). Consequently, the enriched population of the RNA target of interest may comprise at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, or 80%, or any range therein, of the total RNA in the sample.
As used herein, the term “undesirable RNA molecule”, or “undesirable RNA”, refers to an undesired RNA that is the target for depletion from the biological sample. In some embodiments, examples of the undesirable RNA include, but are not limited to, messenger RNA (mRNA), ribosomal RNA (rRNA), mitochondrial RNA (mtRNA), transfer RNA (tRNA), microRNA (miRNA), and viral RNA. In some embodiments, the undesirable RNA can be a transcript (e.g., present in a tissue section). The undesirable RNA can be small (e.g., less than 200 nucleic acid bases in length) or large (e.g., RNA greater than 200 nucleic acid bases in length).
In some embodiments, the undesirable RNA molecule includes 5.8S ribosomal RNA (rRNA), 5S rRNA, transfer RNA (tRNA), microRNA (miRNA), a small nucleolar RNA (snoRNAs), Piwi-interacting RNA (piRNA), tRNA-derived small RNA (tsRNA), and small rDNA-derived RNA (srRNA), or mitochondrial RNA (mtRNA). In some embodiments, the undesirable RNA molecule includes an RNA molecule that is added (e.g., transfected) into a sample (e.g., a small interfering RNA (siRNA)). The undesirable RNA can be double-stranded RNA or single-stranded RNA. In embodiments where the undesirable RNA is double-stranded it is processed as a single-stranded RNA prior to depletion. In some embodiments, the undesirable RNA can be circular RNA. In some embodiments, the undesirable RNA can be a bacterial rRNA (e.g., 16s rRNA or 23s rRNA). In some embodiments, the undesirable RNA is from E. coli.
In some embodiments, the undesirable RNA molecule is rRNA. In some embodiments, the rRNA is eukaryotic rRNA. In some embodiments, the rRNA is cytoplasmic rRNA. In some embodiments, the rRNA is mitochondrial rRNA. Cytoplasmic rRNAs include, for example, 28S, 5.8S, 5S and 18S rRNAs. Mitochondrial rRNAs include, for example, 12S and 16S rRNAs. The rRNA may also be prokaryotic rRNA, which includes, for example, 5S, 16S, and 23S rRNA. The sequences for rRNAs are well known to those skilled in the art and can be readily found in sequence databases such as GenBank or may be found in the literature. For example, the sequence for the human 18S rRNA can be found in GenBank as Accession No. M10098 and the human 28S rRNA as Accession No. M11167.
In some embodiments, the undesirable RNA molecule is mitochondrial RNA. Mitochondrial RNAs include, for example, 12S rRNA (encoded by MT-RNR1), and 16S rRNA (encoded by MT-RNR2), RNAs encoding electron transport chain proteins (e.g., NADH dehydrogenase, coenzyme Q-cytochrome c reductase/cytochrome b, cytochrome c oxidase, ATP synthase, or humanin), and tRNAs (encoded by MT-TA, MT-TR, MT-TN, MT-TD, MT-TC, MT-TE, MT-TQ, MT-TG, MT-TH, MT-TI, MT-TL1, MT-TL2, MT-TK, MT-TM, MT-TF, MT-TP, MT-TS1, MT-TS2, MT-TT, MT-TW, MT-TY, or MT-TV).
In some embodiments, the one or more undesirable RNA depletion probes is a DNA probe. In some embodiments, the DNA probe includes a single-stranded DNA oligonucleotide having a sequence partially or completely complementary to an undesirable RNA and specifically hybridizes to the undesirable RNA. In some embodiments, the one or more undesirable RNA depletion probes are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% complementary to one or more undesirable RNA molecules. In some embodiments, the one or more undesirable RNA depletion probes is 100% (i.e., completely) complementary to one or more undesirable RNA molecules.
In some embodiments, probes used herein have been described in Morlan et al., PLOS One. 2012; 7(8):e42882, which is incorporated by reference in its entirety. In some embodiments, probes used herein have been described in U.S. Appl. Publ. No. 2011/0111409, which is incorporated by reference in its entirety. In some embodiments, probes used herein have been described in Adiconis et al., Nat Methods. 2013 July; 10(7):623-9, which is incorporated by reference in its entirety.
The DNA probe can be produced by techniques known in the art. For example, in some embodiments, a DNA probe is produced by chemical synthesis, by in vitro expression from recombinant nucleic acid molecules, or by in vivo expression from recombinant nucleic acid molecules. The undesirable RNA depletion probe may also be produced by amplification of the undesirable RNA, e.g., RT-PCR, asymmetric PCR, or rolling circle amplification.
As discussed, undetectable levels of T-cell receptor and B-cell receptor transcripts were captured with poly(T) capture domains as shown in
A strategy to detect whether analytes encoding immune cell receptors were captured was investigated and includes using poly(T) capture sequences in combination with PCR amplification performed on full length cDNA from several different sources, including lymph node tissue and tonsil tissue (Table 1).
The tonsil SS2 sample was derived from the same tonsil as the tonsil spatial libraries and adapted from Picelli et al., Full-length RNA-seq from single cells using Smart-seq2, 9, 171-181, Nature (2014), and used as a positive control and without PCR enrichment.
To begin, 0.5 ng of each library in Table 1 as input material was run in triplicate for each sample and PCR reaction (TRB, IGHG, and IGHM), except for one LN (#9) and the Tonsil SS2 bulk sample, which were run in duplicate and once, respectively. The PCR primers targeted: a) the constant region of either TRB, IGHG, or IGHM (Table 2), and b) the variable segments for TRB (Balazs, A. B., et al., Isolation of unknown rearranged T-cell receptors from single cells WO 2011/008502, which is incorporated herein by reference in its entirety) and IGH (Vázquez, B., et al., High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis, Frontiers Immunol, 10, 660 (2019), which is incorporated herein by reference in its entirety). The constant primers were selected based on their proximity to the CDR3 region and testing of various primers for each target was performed in PCR optimization experiments. Both the forward and reverse primers were tagged with partial P5 and P7 domains that allowed subsequent Truseq indexing for ILLUMINA® (sequencing technology) sequencing. PCR was performed using the KAPA HiFi Hotstart ready mix according to the manufacturer's instructions with 30 amplification cycles.
Variable Region Primer
After PCR enrichment, the PCR product was purified before the PCR indexing reaction. Quant-iT (ThermoFisher Scientific) analysis measured the DNA concentration of each sample, which was also normalized to the input material in the PCR indexing reaction (1.25 ng/reaction). Indexing PCR was performed as previously described (Ståhl, P. L., et al., Visualization and analysis of gene expression in tissue sections by spatial transcriptomics, Science, 353(6294), 78-82, (2016)). In total, 24 unique indexes were used, with each cDNA library receiving a unique index (TRB, IGHG, and IGHM products from the same cDNA library received the same indexing since the TCR and BCR clonotypes can be distinguished from each other bioinformatically using the constant primer sequence). After purification, PCR reactions were pooled. The pooled PCR library was run on a gel and a large band at around 500 bp excised was gel-purified and sequenced (NovaSeq, 2×150 bp). The resulting data were de-multiplexed and the FastQ files were analyzed using MiXCR (Bolotin, D. A., et al., MiXCR: software for comprehensive adaptive immune profiling, Nature Methods, 12, 380-381 (2015), which is incorporated herein by reference in its entirety).
After PCR variable region primer enrichment, a number of TRB and IGH clonotypes in all prepared libraries were detected. For TRB, about 10,000 unique clonotypes were detected in spatial libraries prepared from tonsil tissue (data not shown) and between about 12,000 and about 25,000 unique clonotypes were detected in spatial libraries prepared from lymph node (data not shown). The positive control (SmartSeq2 RNAseq after PCR enrichment) yielded about 35,000 unique clonotypes. Variable region primer enrichment of the Smartseq2 library increased the TRB unique clonotype count over 35-fold, however, the SmartSeq2 library contained RNA extracted from two tonsil sections, whereas only a single tissue section was used for the spatial samples.
Similar results were observed for IGH detection with about 10,000 unique clonotypes detected from spatial libraries prepared from tonsil (
Variable region primer enrichment also resulted in a 4-fold increase in detected clonotypes for single-cell SmartSeq2 libraries. The clonotype increase observed after PCR variable primer enrichment of TRB relative to IGH is consistent with a known lower abundance of TRB transcripts in the cDNA library. For example, it is known that TRA/TRB transcript expression per T-cell is less relative to IGH/IGK/IGL expression per B-cell, and in particular, for plasma cells. Substantial, but not complete overlap, of IGH clonotypes between technical replicates detected in spatial libraries from tonsil tissue was observed. Similarly, substantial, but not complete, overlap of TRB clonotypes between technical replicates detected in spatial libraries from tonsil tissue was also observed. The data show that approximately half the clonotypes from a given technical replicate were detected in at least one or more of the other two technical replicates, which suggests many clonotypes were detected in a given technical replicate, but not all clonotypes were detected in each sample (data not shown). Approximately 10-20 fold increase in clonotype counts were detected with a poly(T) capture domain combined with PCR variable region primer enrichment relative to targeted capture, without variable region primer enrichment.
Collectively, these data show that PCR primer enrichment of analytes encoding immune cell receptors captured by poly(A) capture domains is possible. The use of a poly(A) capture domain allows for the simultaneous capture of analytes that do not encode for immune cell receptors and also does not require a custom array with targeted capture domains.
Preparation of Visium Spatial Gene Expression Libraries
Sections of fresh-frozen breast tumor and tonsil tissue were sliced to 10 μm thickness and mounted onto slides from the Visium Spatial Gene Expression Slide & Reagent kit (10× Genomics® (sequencing technology)). Sequencing libraries were prepared following the manufacturer's protocol (Document number CG000239 Rev A, 10× Genomics® (sequencing technology)). Prior to imaging, coverslips were mounted on the slides according to the protocol's optional step “Coverslip Application & Removal”. Tissue images were taken at 20× magnification using a Metafer Slide Scanning platform (MetaSystems) and raw images were stitched with VSlide software (MetaSystems). Adaptions of the protocol were made in that the Hematoxylin and Eosin (H&E) staining time was reduced to 4 minutes and tissue permeabilization was performed for 12 minutes.
Sequencing and Data Processing of Visium Spatial Gene Expression Libraries
Final sequencing libraries were sequenced on NextSeq™ 2000 (sequencer) (ILLUMINA® (sequencing technology)) with a 28-10-10-150 setup (tonsil), or NovaSeq6000 (ILLUMINA® (sequencing technology)) with a 28-10-10-120 setup (breast tumor). 172M and 93M raw read pairs were obtained from tonsil-1 and tonsil-2, respectively, and 215M and 244M from breast tumor 1 and breast tumor 2, respectively.
Following demultiplexing of the bcl files, read 2 fastq files were trimmed using Cutadapt (Martin, M., Cutadapt removes adapter sequences from high-throughput sequencing reads, EMBnet Journal, 17(1) (2011)) to remove full-length or truncated template switch oligo (TSO) sequences from the 5′ end (e.g., beginning of Read 2) and poly(A) homopolymers from the 3′ end (e.g., end of read 2). The TSO sequence (SEQ ID NO: 114) (AAGCAGTGGTATCAACGCAGAGTACATGGG) was used as a non-internal 5′ adapter with a minimum overlap of 5, meaning that partial matches (up to 5 base pairs) or intact TSO sequences were removed from the 5′ end. The error tolerance was set to 0.1 for the TSO trimming to allow for a maximum of 3 errors. For the 3′ end homopolymer trimming, a sequence of 10 As was used as a regular 3′ adapter to remove potential poly A tail products regardless of its position in the read, also with a minimum overlap of 5 base pairs. The trimmed data was processed with the SpaceRanger pipeline (10× Genomics® (sequencing technology)), version 1.2.1 (tonsil) and version 1.0.0 (BC) and mapped to the GRCH38 v93 genome assembly.
Target Enrichment with Hybridization Capture
TCR and BCR target enrichment was performed using IDT xGen Hybridization and Wash Kit (#1080584) with one enrichment probe pool (IDT) each for BCR and TCR transcripts (IG and TCR pool, Table 3). Custom blocking oligos (IDT, Table 3) were designed to hybridize to adaptor sequences of the cDNA library and to prevent off-target fragments from binding to BCR/TCR transcripts and contaminating the enriched library. The IG and TCR enrichment probe pools were mixed at ratio 1:3 and 1:12, respectively and each sample was enriched using both settings.
The “xGen hybridization capture of DNA libraries”, version 4 (IDT) protocol was followed with an input of 10 μl Visium cDNA per reaction, corresponding to between about 45-130 ng and the hybridization enrichment reaction was performed overnight.
The enriched and purified libraries were amplified twice with an AMPure bead wash after each PCR reaction, using 25 μl 2×KAPA mix, 7.5 μl cDNA primers (10× Genomics® (sequencing technology)) and 17.5 μl sample in MQ water. The following settings were used for the PCRs: 1. 98° C. 3 min; 2. 98° C. 15 sec; 3. 63° C. 30 sec; 4. 72° C. 2 min; 5. Repeat steps 2-5 6× for a total of 7 cycles (1st PCR) and 4× for a total of 5 cycles (2nd PCR); 6. 72° C. 1 min
Library Preparation and Sequencing
The resulting product from the hybridization enrichment capture method was used as input into the SMRTbell library preparation protocol (PacBio). The DNA was concentrated by AMPure Bead Purification (0.8×), eluting in 6 μl of Elution Buffer, using 1 μl for Qubit measurements. At least 1 μg of input was used for each library and multiplexed 8 samples in total per sequencing run. PacBio Barcoded Overhand Adapters was used for multiplexing and followed the manufacturer's instructions for the library preparations. The pooled library had a concentration of 11.4 ng/μl (50 μl total eluted volume). A SMRT Enzyme clean up kit was used to remove linear and single stranded DNA. The final libraries were sequenced at 2.7 million long read sequences (168-422K reads/sample) on a Sequel II at the National Genomics Infrastructure (NGI)/Uppsala Genome Center.
Sequencing Data Analysis
The input for the analysis was de-multiplexed consensus reads obtained from PacBio sequencing and performed with Python programming language. The fastq files were parsed into a dataframe with readID, sequence and quality columns. Data was searched for the Truseq adapter sequence and the TSO sequence to anchor the ends of each of the reads, and reads that lacked these sequences were discarded. A portion of the Truseq adapter starting in the first seven bases of either the read or its reverse complement was identified. If any of the positions matched the sequence with hamming distance 1 or less they were tagged. The same was performed for a portion of the TSO sequence. The sequences were reverse complemented as needed so that all the reads had the Truseq adapter (SEQ ID NO: 115) at the beginning and the TSO (SEQ ID NO: 114) at the end. The spatial barcode and the UMI were identified. The first 16 bases were obtained following the TruSeq adapter to determine the spatial barcode and subsequent bases determined the unique molecular identifier (UMI). Additionally, following the sequence of the UMI at least 4 bases were identified as all thymines (e.g., the poly(dT) capture domain) and filtered out of the reads that had any other bases within that interval. Any read with a UMI identified as a poly(dT) sequence was removed. The end of poly(dT) region is defined as the first matching position for the pattern ‘[{circumflex over ( )}T]T{0,2}[{circumflex over ( )}T]T{0,2}[{circumflex over ( )}T]’.
Clonality Analysis and Visualization
To run MIXCR (version 3.0.3), poly(dT) and TSO sequences were trimmed and the reads were written to a new fastq file. The reads were analyzed with MIXCR and the following command:
The following MIXCR command was performed to report alignments for each read:
The resulting tabular file was used to assign reads to the clonotypes in MIXCR output. Any reads that did not map to any clone were filtered out (cloneID==−1), then the reads were grouped in a table by the spatial barcode and UMI and counted how many reads were present and how many clones were associated with each UMI. UMIs that were assigned to more than one clonotype were filtered out, since they are likely due to PCR or sequencing errors.
The resulting clonotype count matrices were subsequently loaded into R (R Core Team, A language and environment for statistical computing, R Foundation for Statistical Computing, (2017)). Tissue images, spatial coordinates and total gene expression counts obtained through the Visium platform and SpaceRanger pipeline were also loaded, and one Seurat object (Stuart et al. Comprehensive Integration of Single-Cell Data, Cell, 177(7) (2019)) per sample type (tonsil and breast tumor tumor) was created using the STutility package (Bergenstråhle et al., Seamless integration of image and molecular analysis for spatial transcriptomics workflows, BMC Genomics, 21(1), (2020)). The clonotype count matrix was extended by adding any missing spatial barcodes that were present in the total gene expression count matrix, and filled with zero counts for all added barcodes. The new, extended matrix was loaded as a new assay into the Seurat object, where genes and clonotypes were visualized on the tissue images using built-in functions of the STUtility package.
Cell Processing for Single-Cell RNA Sequencing
Single cell suspensions from five breast tumor regions (Tumor A-E) were prepared by enzymatic tissue dissociation using the human Tumor Dissociation Kit (Miltenyi Biotec, 130-095-929) and gentleMACS dissociator (Miltenyi Biotec). Cell suspensions were stained with the Zombie Aqua Fixable viability dye (Biolegend, 423101) at room temperature for 20 minutes, then washed with Phosphate Buffered Saline (PBS). The cells were incubated with Human TruStain Fc block (Biolegend, 422302) for 10 minutes to limit non-specific antibody binding, then stained for 20 minutes with anti-EPCAM (1:40, Biolegend, 324206) and anti-CD45 (1:40, Biolegend, 304021) in FACS buffer (PBS+0.5% Bovine Serum Albumin). The cells were subsequently washed and resuspended in FACS buffer. Fluorescence-activated cell sorting (FACS) using an influx flow cytometer (BD Biosciences) was performed to sort live EPCAM+CD45+ single cells an Eppendorf tube for 10× Genomics® (sequencing technology) Chromium Single Cell gene expression analysis. Single stain controls (e.g., cells and beads) and fluorescence minus one controls (FMO), containing all the fluorochromes in the panel except the one being measured, were used to set voltages and to define the proper gating strategy.
10× Genomics R (Sequencing Technology) Chromium Single-Cell Library Preparation and Sequencing
Single-cell gene expression and VDJ clonotype libraries were generated from EPCAM-CD45+ cells using the 10× Genomics® (sequencing technology) Chromium Single Cell 5′ assay following the manufacturer's instructions. Libraries were profiled and quantified using a Bioanalyzer High Sensitivity DNA kit (Agilent Technologies) and Qubit High sensitivity kit (Thermo Fischer Scientific). Final single-cell gene expression libraries were sequenced (aiming for at least 30,000 reads per cell) on a NovaSeq 6000 SP flowcell (ILLUMINA® (sequencing technology) 150-8-8-150 read set-up) by the National Genomics Infrastructure, SciLifeLab.
Single-Cell Gene Expression and VDJ Data Processing
Sequencing outputs were processed by Cell Ranger (version 5.0, 10× Genomics® (sequencing technology)). Gene-barcode count matrices were analyzed with the Seurat package (version 4.0, Satija Lab). Two steps of filtering were introduced here. First, raw gene expression matrices were subset by the barcode list in VDJ output, including T cell subsets and B cell subsets. Based on the UMI count, gene count, and mitochondrial percentage of raw gene expression matrices and their subsets, each threshold was selected to keep the maximum count of high-quality cells and avoid losing T and B cells which have VDJ sequencing outputs. Second, doublets in each sample were detected and filtered out by HTODemux( ) function in Seurat. All samples were integrated and scaled into one count matrix by Seurat. Dimension reduction, UMAP generation, and clustering, were performed on the merged dataset by Seurat. The merged dataset was clustered by a gradient of the resolution, from 0.2 to 2. The final resolution was determined by the significance of top-listed differentially expressed genes in each cluster. Cell types were annotated by differentially expressed genes and their marker genes expression level. All dimension reduction and annotation results, along with the VDJ output files were imported into Loupe Browser (version 5.0, 10× Genomics® (sequencing technology)) and Loupe VDJ Browser (version 4.0, 10× Genomics® (sequencing technology)) for interactive analysis.
Semi-Nested PCR
After hybridization capture and post-capture PCR amplification (14 cycles), semi-nested PCR reactions were performed with the following primers: V primers targeting either the TRAV or TRBV genes, 5′ of the CDR3 region (i.e. ‘Outer’ TRAV or TRBV primers, see Table 3 for sequences) and a primer (‘partRead1’, see Table 3) targeting the universal partial read 1 sequence present on the transcripts in Visium cDNA libraries. PartRead1 is also compatible with TruSeq indexes to allow multiplexing of samples for sequencing. For the semi-nested PCR experiments, the Visium cDNA was further pre-amplified prior to hybridization capture to generate more input needed for testing. The Outer V primer PCR input was 1-5 ng of hybridization captured cDNA from two breast tumor tissue Visium libraries (replicate, adjacent sections) and the reaction was run with KAPA HiFi HotStart ReadyMix (2×) (KAPA Biosystems). All primers were diluted 40× for a final concentration of 2.5 μM (Integrated DNA Technologies). The PCR was run for 15 cycles under the following conditions: 1. 98° C. 5 min; 2. 98° C. 20 sec; 3. 65° C. 30 sec; 4. 72° C. 1:30 min; 5. Repeat steps 2-5 14× for a total of 15 cycles; and 6. 72° C. 7 min.
Quantitative real-time PCR (qPCR) was performed to determine the appropriate number of cycles (to avoid exponential amplification). The Outer V primer PCR product was purified using AMPure beads (0.6×), followed by two 80% EtOH washes. The Outer V primer PCR product was eluted in EB buffer after incubation at 15 min at 37° C. The cleaned up PCR product was quantified using Qubit and BioAnalyzer (Agilent). 3-5 ng of each PCR product was used as input to the subsequent Inner V primer PCR.
The Inner V primer PCR was performed with the following primers: V primers targeting either the TRAV or the TRBV gene, close/adjacent to the CDR3 region (e.g., ‘Inner’ V primers) and the same universal partial read 1 primer as described for the Outer V primer PCR (‘partRead1’). These Inner V primers have a handle compatible with TruSeq indexing. The primer concentrations and reagents were as described for the OUTER V primer PCR. qPCR was used to determine the optimal number of cycles (7). The following conditions were used for the PCR reaction: 7. 98° C. 5 min; 8. 98° C. 20 sec; 9. 72° C. 30 sec; 10. 72° C. 1:30 min; 11. Repeat steps 2-5 14× for a total of 15 cycles; 12. 72° C. 7 min.
The same AMPure bead-clean up and ethanol washes were performed as described above. The final eluted PCR product was quantified using Qubit and BioAnalyzer (Agilent). The samples were PCR indexed using TruSeq Indexes (5 cycles) and sequenced on a Novaseq sequencing instrument using a short read 1 and a longer read 2 to capture the entire CDR3 region and part of the constant region from the 5′ end.
Target Enrichment with Hybridization Capture for TOR and BOR Sequences
As discussed above BCR (IGH, IGK, IGL) and TCR (TRA, TRB) clones can be amplified using PCR from poly(dT) captured cDNA libraries, e.g., Visium (10× Genomics® (sequencing technology)). In some instances, the obtained amplicons lacked the spatial barcode. Therefore, to enrich for TCR and BCR sequences while preserving the spatial barcode and the CDR3 clonal information, a target enrichment strategy with hybridization probes (IDT technologies) was tested. Manufacturer's instructions were followed with some minor adaptations according to the methods described above. Visium cDNA from two tonsil sections (e.g., from the same tonsil, spaced 150 μM apart) were used as input material.
Clonotype Numbers
cDNA prepared from captured immune cell mRNA analytes were enriched via a hybridization capture approach as described above and combined with PacBio long read sequencing. The resulting data successfully identified spatially barcoded BCR and TCR clones from tonsil Visium libraries (
Collectively, the data demonstrate that target enrichment with hybridization probes from Visium cDNA mRNA libraries successfully enrich BCR and TCR clones from lymphocyte rich tissue.
B and T cell Spatial Segregation in the Tonsil
It was expected that with tonsil and similar tissues, e.g., lymph node, B cell clones would segregate mainly in follicles or germinal centers, in which B cell clonal selection and expansion occurs. In the Visium gene expression data, MS4A1, which encodes CD20 a B cell specific gene, was expressed in a cluster-like pattern that corresponded with increased cell density as visualized by the H&E staining, suggestive of B cell follicles (“B cell follicles”) (
Clonotype Distribution in the Tonsil
The data determined whether captured clones spatially segregate in tonsil tissue relative to the observed B and T cell segregation (
Target Enrichment of Lymphocyte Receptors in Breast Tumor Tissue
Target enrichment strategies as described herein were also tested on breast tumor tissue. Due to the high frequency of tumor cells and stromal cells in breast tumor tissue, it was expected that lymphocyte-associated transcripts would be less abundant, relative to tonsil tissue. Visium libraries were generated from two consecutive sections from breast tumor tissue, isolated from a HER2+ breast tumor patient.
Spatial segregation of IGH clones (e.g., IGHV4-28, IGHD3-3, IGHD3-9, IGHJ4, IGHG1/IGHG3) within the breast tumor tissue was found consistent between two adjacent sections (See
Target Enrichment for TOR Using Semi-Nested PCR
As described above, the hybridization probe approach was more efficient at capturing BCR clonotypes, most probably due to higher expression on a per cell basis than TCR clonotypes. In order to improve TCR capture, a second target enrichment step was introduced to increase the T cell clonotype yield and to prepare libraries compatible with ILLUMINA® (sequencing technology) sequencing. After hybridization probe capture and subsequent PCR amplification, TCR analytes were enriched using a semi-nested PCR approach as shown in
The results show amplification of both TRA and TRB transcripts using the semi-nested PCR approach from breast tumor Visium libraries and that these libraries had the expected sizes (data not shown).
Collectively, the data demonstrate that spatial transcriptomics for antigen receptors can isolate high numbers of BCR and TCR clonotypes from tonsil and breast tumor tissue. These clones segregate in the tissue in characteristic ways concordant with their biology and cell type gene expression patterns.
Embodiment 1 is a method for determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample, the method comprising: (a) contacting a biological sample with an array comprising a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises (i) a spatial barcode and (ii) a capture domain that specifically binds to a nucleic acid encoding an immune cell receptor of the immune cell clonotype; and (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell clonotype at a location in the biological sample.
Embodiment 2 is the method of embodiment 1, wherein the immune cell clonotype is a T cell clonotype.
Embodiment 3. The method of embodiment 2, wherein the immune cell receptor is a T cell receptor alpha chain.
Embodiment 4 is the method of embodiment 3, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain.
Embodiment 5 is the method of embodiment 3 or 4, wherein step (b) comprises determining a sequence encoding CDR3 of the T cell receptor alpha chain.
Embodiment 6 is the method of embodiment 5, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor alpha chain.
Embodiment 7 is the method of embodiment 5, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the T cell receptor alpha chain.
Embodiment 8 is the method of embodiment 2, wherein the immune cell receptor is a T cell receptor beta chain.
Embodiment 9 is the method of embodiment 8, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain.
Embodiment 10 is the method of embodiment 8 or 9, wherein step (b) comprises determining a sequence encoding CDR3 of the T cell receptor beta chain.
Embodiment 11 is the method of embodiment 10, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor beta chain.
Embodiment 12 is the method of embodiment 10, wherein step (b) further comprises determining a full-length variable domain of the T cell receptor beta chain.
Embodiment 13 is the method of embodiment 1, wherein the immune cell clonotype is a B cell clonotype.
Embodiment 14 is the method of embodiment 13, wherein the immune cell receptor is an immunoglobulin kappa light chain.
Embodiment 15 is the method of embodiment 14, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain.
Embodiment 16 is the method of embodiment 14 or 15, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin kappa light chain.
Embodiment 17 is the method of embodiment 16, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain.
Embodiment 18 is the method of embodiment 16, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin kappa light chain.
Embodiment 19 is the method of embodiment 13, wherein the immune cell receptor is an immunoglobulin lambda light chain.
Embodiment 20 is the method of embodiment 19, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain.
Embodiment 21 is the method of embodiment 19 or 20, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin lambda light chain.
Embodiment 22 is the method of embodiment 21, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain.
Embodiment 23 is the method of embodiment 21, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin lambda light chain.
Embodiment 24 is the method of embodiment 13, wherein the immune cell receptor is an immunoglobulin heavy chain.
Embodiment 25 is the method of embodiment 24, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain.
Embodiment 26 is the method of embodiment 24 or 25, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin heavy chain.
Embodiment 27 is the method of embodiment 26, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin heavy chain.
Embodiment 28 is the method of embodiment 26, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin heavy chain.
Embodiment 29 is the method of any one of embodiments 1-28, wherein step (b) comprises the capture probe using the nucleic acid encoding the immune cell receptor as a template, thereby generating an extended capture probe.
Embodiment 30 is the method of embodiment 29, wherein step (b) comprises extending a 3′ end of the capture probe.
Embodiment 31 is the method of embodiment 29 or 30, wherein step (b) further comprises generating a second strand of nucleic acid that comprises (i) a sequence that is complementary to all or a portion of the spatial barcode, and (ii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
Embodiment 32 is the method of any one of embodiments 1-31, wherein the capture probe further comprises a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof.
Embodiment 33 is the method of any one of embodiments 1-30, wherein the capture probe further comprises a functional domain.
Embodiment 34 is the method of embodiment 33, wherein step (b) further comprises generating a second strand of nucleic acid that comprises (i) a sequence that is complementary to all or a portion of the functional domain, (ii) a sequence that is complementary to all or a portion of the spatial barcode, and (iii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
Embodiment 35 is the method of embodiment 34, wherein step (b) further comprises amplifying the second strand of nucleic acid using (i) a first primer comprising all or a portion of the functional domain, wherein the functional domain is 5′ to the spatial barcode in the second strand of nucleic acid, and (ii) a second primer comprising a sequence that is substantially complementary to a portion of a sequence encoding a variable region of the immune cell receptor.
Embodiment 36 is the method of any one of embodiments 1-35, wherein the biological sample comprises a tissue sample.
Embodiment 37 is the method of embodiment 36, wherein the tissue sample is a tissue section.
Embodiment 38 is the method of embodiment 37, wherein the tissue section is a fixed tissue section.
Embodiment 39 is the method of embodiment 38, wherein the fixed tissue section is a formalin-fixed paraffin-embedded tissue section.
Embodiment 40 is the method of any one of embodiments 37-39, wherein the tissue section comprises a tumor region.
Embodiment 41 is the method of any one of embodiments 1-40, wherein the nucleic acid encoding the immune cell receptor comprises RNA.
Embodiment 42 is the method of embodiment 41, wherein the RNA is mRNA.
Embodiment 43 is the method of any one of embodiments 1-40, wherein the nucleic acid encoding the immune cell receptor comprises DNA.
Embodiment 44 is the method of embodiment 43, wherein the DNA is genomic DNA.
Embodiment 45 is the method of any one of embodiments 1-44, wherein the method further comprises, prior to step (b), contacting the biological sample with ribosomal RNA depletion probes and mitochondrial RNA depletion probes.
Embodiment 46 is the method of any one of embodiments 1-45, wherein the method further comprises imaging the biological sample.
Embodiment 47 is the method of any one of embodiments 1-46, wherein the determining in step (b) comprises sequencing (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof.
Embodiment 48 is the method of any one of embodiments 1-47, wherein step (b) comprises determining the presence of the immune cell clonotype at a location in the biological sample.
Embodiment 49 is the method of any one of embodiments 1-47, wherein step (b) comprises determining the abundance of the immune cell clonotype at a location in the biological sample.
Embodiment 50 is the method of any one of embodiments 1-47, wherein step (b) comprises determining the presence and abundance of the immune cell clonotype at a location in the biological sample.
Embodiment 51 is the method of any one of embodiments 1-47, wherein step (b) comprises determining the presence of two or more immune cell clonotypes at a location in the biological sample.
Embodiment 52 is the method of any one of embodiments 1-47, wherein step (b) comprises determining the abundance of two or more immune cell clonotypes at a location in the biological sample.
Embodiment 53 is the method of any one of embodiments 1-47, wherein step (b) comprises determining the presence and abundance of two or more immune cell clonotypes at a location in the biological sample.
Embodiment 54 is the method of any one of embodiments 51-53, wherein the method further comprises comparing the two or more immune cell clonotypes.
Embodiment 55 is the method of any one of embodiments 51-54, wherein the two or more immune cell clonotypes are each a B cell clonotype.
Embodiment 56 is the method of any one of embodiments 51-54, wherein the two or more immune cell clonotypes are each a T cell clonotype.
Embodiment 57 is the method of any one of embodiments 51-54, wherein the two or more immune cell clonotypes comprise at least one T cell clonotype and at least one B cell clonotype.
Embodiment 58 is a method for determining the presence and/or abundance of an immune cell receptor at a location in a biological sample, the method comprising: (a) contacting a biological sample with an array comprising a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises (i) a spatial barcode and (ii) a capture domain that specifically binds to a nucleic acid encoding an immune cell receptor; and (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell receptor at a location in the biological sample.
Embodiment 59 is the method of embodiment 58, wherein the immune cell receptor is a T cell receptor alpha chain.
Embodiment 60 is the method of embodiment 59, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain.
Embodiment 61 is the method of embodiment 59 or 60, wherein step (b) comprises determining a sequence encoding CDR3 of the T cell receptor alpha chain.
Embodiment 62 is the method of embodiment 61, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor alpha chain.
Embodiment 63 is the method of embodiment 61, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the T cell receptor alpha chain.
Embodiment 64 is the method of embodiment 58, wherein the immune cell receptor is a T cell receptor beta chain.
Embodiment 65 is the method of embodiment 64, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain.
Embodiment 66 is the method of embodiment 64 or 65, wherein step (b) comprises determining a sequence encoding CDR3 of the T cell receptor beta chain.
Embodiment 67 is the method of embodiment 66, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor beta chain.
Embodiment 68 is the method of embodiment 66, wherein step (b) further comprises determining a full-length variable domain of the T cell receptor beta chain.
Embodiment 69 is the method of embodiment 58, wherein the immune cell receptor is an immunoglobulin kappa light chain.
Embodiment 70 is the method of embodiment 69, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain.
Embodiment 71 is the method of embodiment 69 or 70, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin kappa light chain.
Embodiment 72 is the method of embodiment 71, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain.
Embodiment 73 is the method of embodiment 71, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin kappa light chain.
Embodiment 74 is the method of embodiment 58, wherein the immune cell receptor is an immunoglobulin lambda light chain.
Embodiment 75 is the method of embodiment 74, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain.
Embodiment 76 is the method of embodiment 74 or 75, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin lambda light chain.
Embodiment 77 is the method of embodiment 76, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain.
Embodiment 78 is the method of embodiment 76, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin lambda light chain.
Embodiment 79 is the method of embodiment 58, wherein the immune cell receptor is an immunoglobulin heavy chain.
Embodiment 80 is the method of embodiment 79, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain.
Embodiment 81 is the method of embodiment 79 or 80, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin heavy chain.
Embodiment 82 is the method of embodiment 81, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin heavy chain.
Embodiment 83 is the method of embodiment 81, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin heavy chain.
Embodiment 84 is the method of any one of embodiments 58-83, wherein step (b) comprises extending an end of the capture probe using the nucleic acid encoding the immune cell receptor as a template, thereby generating an extended capture probe.
Embodiment 85 is the method of embodiment 84, wherein step (b) comprises extending a 3′ end of the capture probe.
Embodiment 86 is the method of embodiment 84 or 85, wherein step (b) further comprises generating a second strand of nucleic acid that comprises (i) a sequence that is complementary to all or a portion of the spatial barcode, and (ii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
Embodiment 87 is the method of any one of embodiments 58-86, where the capture probe further comprises a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof.
Embodiment 88 is the method of any one of embodiments 58-85, wherein the capture probe further comprises a functional domain.
Embodiment 89 is the method of embodiment 88, wherein step (b) further comprises generating a second strand of nucleic acid that comprises (i) a sequence that is complementary to all or a portion of the functional domain, (ii) a sequence that is complementary to all or a portion of the spatial barcode, and (iii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
Embodiment 90 is the method of embodiment 89, wherein step (b) further comprises amplifying the second strand of nucleic acid using (i) a first primer comprising all or a portion of the functional domain, wherein the functional domain is 5′ to the spatial barcode in the second strand of nucleic acid, and (ii) a second primer comprising a sequence that is substantially complementary to a portion of a sequence encoding a variable region of the immune cell receptor.
Embodiment 91 is the method of any one of embodiments 58-90, wherein the biological sample comprises a tissue sample.
Embodiment 92 is the method of embodiment 91, wherein the tissue sample is a tissue section.
Embodiment 93 is the method of embodiment 92, wherein the tissue section is a fixed tissue section.
Embodiment 94 is the method of embodiment 93, wherein the fixed tissue section is a formalin-fixed paraffin-embedded tissue section.
Embodiment 95 is the method of any one of embodiments 92-94, wherein the tissue section comprises a tumor region.
Embodiment 96 is the method of any one of embodiments 58-95, wherein the nucleic acid encoding the immune cell receptor comprises RNA.
Embodiment 97 is the method of embodiment 96, wherein the RNA is mRNA.
Embodiment 98 is the method of any one of embodiments 58-95, wherein the nucleic acid encoding the immune cell receptor comprises DNA.
Embodiment 99 is the method of embodiment 98, wherein the DNA is genomic DNA.
Embodiment 100 is the method of any one of embodiments 58-99, wherein the method further comprises, prior to step (b), contacting the biological sample with ribosomal RNA depletion probes and mitochondrial RNA depletion probes.
Embodiment 101 is the method of any one of embodiments 58-100, wherein the method further comprises imaging the biological sample.
Embodiment 102 is the method of any one of embodiments 58-101, wherein the determining in step (b) comprises sequencing (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof.
Embodiment 103 is the method of any one of embodiments 58-102, wherein step (b) comprises determining the presence of the immune cell receptor at a location in the biological sample.
Embodiment 104 is the method of any one of embodiments 58-102, wherein step (b) comprises determining the abundance of the immune cell receptor at a location in the biological sample.
Embodiment 105 is the method of any one of embodiments 58-102, wherein step (b) comprises determining the presence and abundance of the immune cell receptor at a location in the biological sample.
Embodiment 106 is the method of any one of embodiments 58-102, wherein step (b) comprises determining the presence of two or more immune cell receptors at a location in the biological sample.
Embodiment 107 is the method of any one of embodiments 58-102, wherein step (b) comprises determining the abundance of two or more immune cell receptors at a location in the biological sample.
Embodiment 108 is the method of any one of embodiments 58-102, wherein step (b) comprises determining the presence and abundance of two or more immune cell receptors at a location in the biological sample.
Embodiment 109 is the method of any one of embodiments 106-108, wherein the method further comprises comparing the two or more immune cell receptors.
Embodiment 110 is the method of any one of embodiments 106-109, wherein the two or more immune cell clonotypes are each an immune cell receptor of a B cell.
Embodiment 111 is the method of any one of embodiments 106-109, wherein the two or more immune cell clonotypes are each an immune cell receptor of a T cell.
Embodiment 112 is the method of any one of embodiments 106-109, wherein the two or more immune cell clonotypes comprise at least one immune cell receptor of a T cell and at least one immune cell receptor from a B cell.
Embodiment 113 is an array comprising a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises (i) a spatial barcode and (ii) a capture domain that specifically binds to a nucleic acid encoding an immune cell receptor of an immune cell clonotype.
Embodiment 114 is the array of embodiment 113, wherein the immune cell clonotype is a T cell clonotype.
Embodiment 115 is the array of embodiment 114, wherein the immune cell receptor is a T cell receptor alpha chain.
Embodiment 116 is the array of embodiment 115, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor alpha chain.
Embodiment 117 is the array of embodiment 114, wherein the immune cell receptor is a T cell receptor beta chain.
Embodiment 118 is the array of embodiment 117, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the T cell receptor beta chain.
Embodiment 119 is the array of embodiment 113, wherein the immune cell clonotype is a B cell clonotype.
Embodiment 120 is the array of embodiment 119, wherein the immune cell receptor is an immunoglobulin kappa light chain.
Embodiment 121 is the array of embodiment 120, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin kappa light chain.
Embodiment 122 is the array of embodiment 119, wherein the immune cell receptor is an immunoglobulin lambda light chain.
Embodiment 123 is the array of embodiment 122, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin lambda light chain.
Embodiment 124 is the array of embodiment 119, wherein the immune cell receptor is an immunoglobulin heavy chain.
Embodiment 125 is the array of embodiment 124, wherein the capture domain binds specifically to a nucleic acid sequence encoding a constant region of the immunoglobulin heavy chain.
Embodiment 126 is the array of any one of embodiments 113-125, where the capture probe further comprises a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof.
Embodiment 127. A kit comprising: an array of any one of embodiments 113-126; and one or both of ribosomal RNA depletion probes and mitochondrial RNA depletion probes.
Embodiment 128 is a method for determining the presence and/or abundance of an immune cell clonotype at a location in a biological sample, the method comprising: (a) contacting a biological sample with an array comprising a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises (i) a spatial barcode and (ii) a capture domain that binds to a nucleic acid encoding an immune cell receptor of the immune cell clonotype; (b) determining (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof, and using the determined sequences of (i) and (ii) to determine the presence and/or abundance of the immune cell clonotype at a location in the biological sample.
Embodiment 129 is the method of embodiment 1, wherein step (b) comprises extending the capture probe using the nucleic acid encoding the immune cell receptor as a template, thereby generating an extended capture probe.
Embodiment 130 is the method of embodiment 129, wherein step (b) comprises extending a 3′ end of the capture probe.
Embodiment 131 is the method of embodiment 129 or 130, wherein step (b) further comprises generating a second strand of nucleic acid that comprises (i) a sequence that is complementary to all or a portion of the spatial barcode, and (ii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
Embodiment 132 is the method of any one of embodiments 128-131, wherein the capture probe further comprises a cleavage domain, a functional domain, a unique molecular identifier, or any combination thereof.
Embodiment 133 is the method of any one embodiments 128-132, wherein the capture domain comprises a poly(T) sequence.
Embodiment 134 is the method of any one of embodiments 128-133, wherein the capture probe further comprises a functional domain.
Embodiment 135 is the method of embodiment 134, wherein step (b) further comprises generating a second strand of nucleic acid that comprises (i) a sequence that is complementary to all or a portion of the functional domain, (ii) a sequence that is complementary to all or a portion of the spatial barcode, and (iii) a sequence that corresponds to all or a portion of the sequence of the nucleic acid encoding the immune cell receptor.
Embodiment 136 is the method of embodiment 135, wherein step (b) further comprises amplifying the second strand of nucleic acid using (i) a first primer comprising all or a portion of the functional domain, wherein the functional domain is 5′ to the spatial barcode in the second strand of nucleic acid, and (ii) a second primer comprising a sequence that is substantially complementary to a portion of a sequence encoding a variable region of the immune cell receptor.
Embodiment 137 is the method of any one of embodiments 128-136, wherein the immune cell clonotype is a T cell clonotype.
Embodiment 138 is the method of embodiment 137, wherein the immune cell receptor is a T cell receptor alpha chain.
Embodiment 139 is the method of embodiment 138, wherein step (b) comprises determining a sequence encoding CDR3 of the T cell receptor alpha chain.
Embodiment 140 is the method of embodiment 139, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor alpha chain.
Embodiment 141 is the method of embodiment 139, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the T cell receptor alpha chain.
Embodiment 142 is the method of embodiment 137, wherein the immune cell receptor is a T cell receptor beta chain.
Embodiment 143 is the method of embodiment 142, wherein step (b) comprises determining a sequence encoding CDR3 of the T cell receptor beta chain.
Embodiment 144 is the method of embodiment 143, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the T cell receptor beta chain.
Embodiment 145 is the method of embodiment 143, wherein step (b) further comprises determining a full-length variable domain of the T cell receptor beta chain.
Embodiment 146 is the method of any one of embodiments 128-136, wherein the immune cell clonotype is a B cell clonotype.
Embodiment 147 is the method of embodiment 146, wherein the immune cell receptor is an immunoglobulin kappa light chain.
Embodiment 148 is the method of embodiment 147, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin kappa light chain.
Embodiment 149 is the method of embodiment 148, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin kappa light chain.
Embodiment 150 is the method of embodiment 148, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin kappa light chain.
Embodiment 151 is the method of embodiment 146, wherein the immune cell receptor is an immunoglobulin lambda light chain.
Embodiment 152 is the method of embodiment 151, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin lambda light chain.
Embodiment 153 is the method of embodiment 152, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain.
Embodiment 154 is the method of embodiment 152, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin lambda light chain.
Embodiment 155 is the method of embodiment 146, wherein the immune cell receptor is an immunoglobulin heavy chain.
Embodiment 156 is the method of embodiment 155, wherein step (b) comprises determining a sequence encoding CDR3 of the immunoglobulin heavy chain.
Embodiment 157 is the method of embodiment 156, wherein step (b) further comprises determining a sequence encoding one or both of CDR1 and CDR2 of the immunoglobulin heavy chain.
Embodiment 158 is the method of embodiment 156, wherein step (b) further comprises determining a sequence encoding a full-length variable domain of the immunoglobulin heavy chain.
Embodiment 159 is the method of any one of embodiments 128-158, wherein the biological sample comprises a tissue sample.
Embodiment 160 is the method of embodiment 159, wherein the tissue sample is a tissue section.
Embodiment 161 is the method of embodiment 160, wherein the tissue section is a fixed tissue section.
Embodiment 162 is the method of embodiment 161, wherein the fixed tissue section is a formalin-fixed paraffin-embedded tissue section.
Embodiment 163 is the method of any one of embodiments 160-162, wherein the tissue section comprises a tumor region.
Embodiment 164 is the method of any one of embodiments 128-163, wherein the nucleic acid encoding the immune cell receptor comprises RNA.
Embodiment 165 is the method of embodiment 164, wherein the RNA is mRNA.
Embodiment 166 is the method of any one of embodiments 128-163, wherein the nucleic acid encoding the immune cell receptor comprises DNA.
Embodiment 167 is the method of embodiment 166, wherein the DNA is genomic DNA.
Embodiment 168 is the method of any one of embodiments 128-167, wherein the method further comprises, prior to step (b), contacting the biological sample with ribosomal RNA depletion probes and mitochondrial RNA depletion probes.
Embodiment 169 is the method of any one of embodiments 128-168, wherein the method further comprises imaging the biological sample.
Embodiment 170 is the method of any one of embodiments 128-169, wherein the determining in step (b) comprises sequencing (i) all or a portion of the sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of the sequence of the nucleic acid encoding the immune cell receptor or a complement thereof.
Embodiment 171 is the method of any one of embodiments 128-170, wherein step (b) comprises determining the presence of the immune cell clonotype at a location in the biological sample.
Embodiment 172 is the method of any one of embodiments 128-171, wherein step (b) comprises determining the abundance of the immune cell clonotype at a location in the biological sample.
Embodiment 173 is the method of any one of embodiments 128-172, wherein step (b) comprises determining the presence and abundance of the immune cell clonotype at a location in the biological sample.
Embodiment 174 is the method of any one of embodiments 128-173, wherein step (b) comprises determining the presence of two or more immune cell clonotypes at a location in the biological sample.
Embodiment 175 is the method of any one of embodiments 128-174, wherein step (b) comprises determining the abundance of two or more immune cell clonotypes at a location in the biological sample.
Embodiment 176 is the method of any one of embodiments 128-174, wherein step (b) comprises determining the presence and abundance of two or more immune cell clonotypes at a location in the biological sample.
Embodiment 177 is the method of any one of embodiments 174-176, wherein the method further comprises comparing the two or more immune cell clonotypes.
Embodiment 178 is the method of any one of embodiments 174-177, wherein the two or more immune cell clonotypes are each a B cell clonotype.
Embodiment 179 is the method of any one of embodiments 174-177, wherein the two or more immune cell clonotypes are each a T cell clonotype.
Embodiment 180 is the method of any one of embodiments 174-177, wherein the two or more immune cell clonotypes comprise at least one T cell clonotype and at least one B cell clonotype.
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition section headings, the materials, methods, and examples are illustrative only and not intended to be limiting.
This application is a continuation of U.S. patent application Ser. No. 18/315,289, now U.S. U.S. Pat. No. 11,845,979, filed May 10, 2023, which is application is a continuation of U.S. patent application Ser. No. 17/552,135, now U.S. Pat. No. 11,692,218, filed Dec. 15, 2021, which is a continuation of International Patent Application No. PCT/US2021/035242 with an international filing date of Jun. 1, 2021, which claims priority to U.S. Provisional Patent Application Ser. No. 63/033,568, filed on Jun. 2, 2020, the contents of each of which are incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4683195 | Mullis | Jul 1987 | A |
| 4683202 | Mullis | Jul 1987 | A |
| 4800159 | Mullis | Jan 1989 | A |
| 4883867 | Lee | Nov 1989 | A |
| 4965188 | Mullis | Oct 1990 | A |
| 5002882 | Lunnen | Mar 1991 | A |
| 5130238 | Malek | Jul 1992 | A |
| 5308751 | Ohkawa | May 1994 | A |
| 5321130 | Yue | Jun 1994 | A |
| 5410030 | Yue | Apr 1995 | A |
| 5436134 | Haugland | Jul 1995 | A |
| 5455166 | Walker | Oct 1995 | A |
| 5494810 | Barany et al. | Feb 1996 | A |
| 5503980 | Cantor | Apr 1996 | A |
| 5512439 | Hornes | Apr 1996 | A |
| 5512462 | Cheng | Apr 1996 | A |
| 5582977 | Yue | Dec 1996 | A |
| 5599675 | Brenner | Feb 1997 | A |
| 5641658 | Adams | Jun 1997 | A |
| 5648245 | Fire et al. | Jul 1997 | A |
| 5658751 | Yue | Aug 1997 | A |
| 5750341 | Macevicz | May 1998 | A |
| 5763175 | Brenner | Jun 1998 | A |
| 5830711 | Barany et al. | Nov 1998 | A |
| 5837832 | Chee et al. | Nov 1998 | A |
| 5854033 | Lizardi | Dec 1998 | A |
| 5863753 | Haugland | Jan 1999 | A |
| 5871921 | Landegren et al. | Feb 1999 | A |
| 5912148 | Eggerding | Jun 1999 | A |
| 6013440 | Lipshutz | Jan 2000 | A |
| 6027889 | Barany et al. | Feb 2000 | A |
| 6060240 | Kamb et al. | May 2000 | A |
| 6130073 | Eggerding | Oct 2000 | A |
| 6143496 | Brown | Nov 2000 | A |
| 6153389 | Haarer | Nov 2000 | A |
| 6165714 | Lane et al. | Dec 2000 | A |
| 6210891 | Nyren | Apr 2001 | B1 |
| 6210894 | Brennan | Apr 2001 | B1 |
| 6214587 | Dattagupta | Apr 2001 | B1 |
| 6258568 | Nyren | Jul 2001 | B1 |
| 6266459 | Walt | Jul 2001 | B1 |
| 6274320 | Rothberg | Aug 2001 | B1 |
| 6300063 | Lipshutz et al. | Oct 2001 | B1 |
| 6309824 | Drmanac | Oct 2001 | B1 |
| 6344316 | Lockhart | Feb 2002 | B1 |
| 6355431 | Chee | Mar 2002 | B1 |
| 6368801 | Faruqi | Apr 2002 | B1 |
| 6401267 | Drmanac | Jun 2002 | B1 |
| 6404907 | Gilchrist | Jun 2002 | B1 |
| 6432360 | Church et al. | Aug 2002 | B1 |
| 6503713 | Rana | Jan 2003 | B1 |
| 6506561 | Cheval et al. | Jan 2003 | B1 |
| 6544732 | Chee | Apr 2003 | B1 |
| 6620584 | Chee | Sep 2003 | B1 |
| 6632641 | Brennan | Oct 2003 | B1 |
| 6699710 | Kononen | Mar 2004 | B1 |
| 6737236 | Pieken et al. | May 2004 | B1 |
| 6770441 | Dickinson | Aug 2004 | B2 |
| 6773886 | Kaufman | Aug 2004 | B2 |
| 6787308 | Balasubramanian | Sep 2004 | B2 |
| 6800453 | Labaer | Oct 2004 | B2 |
| 6812005 | Fan et al. | Nov 2004 | B2 |
| 6828100 | Ronaghi | Dec 2004 | B1 |
| 6833246 | Balasubramanian | Dec 2004 | B2 |
| 6859570 | Walt | Feb 2005 | B2 |
| 6864052 | Drmanac | Mar 2005 | B1 |
| 6878515 | Landegren | Apr 2005 | B1 |
| 6897023 | Fu | May 2005 | B2 |
| 6942968 | Dickinson et al. | Sep 2005 | B1 |
| 6969589 | Patil | Nov 2005 | B2 |
| 7057026 | Barnes | Jun 2006 | B2 |
| 7115400 | Adessi | Oct 2006 | B1 |
| 7118883 | Inoue | Oct 2006 | B2 |
| 7166431 | Chee et al. | Jan 2007 | B2 |
| 7211414 | Hardin | May 2007 | B2 |
| 7255994 | Lao | Aug 2007 | B2 |
| 7258976 | Mitsuhashi | Aug 2007 | B2 |
| 7297518 | Quake | Nov 2007 | B2 |
| 7329492 | Hardin | Feb 2008 | B2 |
| 7361488 | Fan et al. | Apr 2008 | B2 |
| 7378242 | Hurt | May 2008 | B2 |
| 7393665 | Brenner | Jul 2008 | B2 |
| 7405281 | Xu | Jul 2008 | B2 |
| 7407757 | Brenner | Aug 2008 | B2 |
| 7537897 | Brenner | May 2009 | B2 |
| 7563576 | Chee | Jul 2009 | B2 |
| 7582420 | Oliphant et al. | Sep 2009 | B2 |
| 7601498 | Mao | Oct 2009 | B2 |
| 7635566 | Brenner | Dec 2009 | B2 |
| 7674752 | He | Mar 2010 | B2 |
| 7700286 | Stroun et al. | Apr 2010 | B2 |
| 7709198 | Luo et al. | May 2010 | B2 |
| 7776567 | Mao | Aug 2010 | B2 |
| 7803943 | Mao | Sep 2010 | B2 |
| 7910304 | Drmanac | Mar 2011 | B2 |
| 7955794 | Shen et al. | Jun 2011 | B2 |
| 7960119 | Chee | Jun 2011 | B2 |
| 8003354 | Shen et al. | Aug 2011 | B2 |
| 8148068 | Brenner | Apr 2012 | B2 |
| 8206917 | Chee | Jun 2012 | B2 |
| 8288103 | Oliphant | Oct 2012 | B2 |
| 8337851 | Aukerman | Dec 2012 | B2 |
| 8460865 | Chee | Jun 2013 | B2 |
| 8481257 | Van Eijk | Jul 2013 | B2 |
| RE44596 | Stroun et al. | Nov 2013 | E |
| 8603743 | Liu et al. | Dec 2013 | B2 |
| 8604182 | Luo et al. | Dec 2013 | B2 |
| 8685889 | Van Eijk | Apr 2014 | B2 |
| 8748103 | Faham et al. | Jun 2014 | B2 |
| 8815512 | Van Eijk | Aug 2014 | B2 |
| 8835358 | Fodor | Sep 2014 | B2 |
| 8911945 | Van Eijk | Dec 2014 | B2 |
| 8951726 | Luo et al. | Feb 2015 | B2 |
| 9062348 | Van Eijk | Jun 2015 | B1 |
| 9121069 | Lo | Sep 2015 | B2 |
| 9194001 | Brenner | Nov 2015 | B2 |
| 9217176 | Faham | Dec 2015 | B2 |
| 9290808 | Fodor | Mar 2016 | B2 |
| 9290809 | Fodor | Mar 2016 | B2 |
| 9328383 | Van Eijk | May 2016 | B2 |
| 9334536 | Van Eijk | May 2016 | B2 |
| 9340830 | Lipson | May 2016 | B2 |
| 9371598 | Chee | Jun 2016 | B2 |
| 9506061 | Brown et al. | Nov 2016 | B2 |
| 9512487 | Faham et al. | Dec 2016 | B2 |
| 9593365 | Frisen et al. | Mar 2017 | B2 |
| 9644204 | Hindson et al. | May 2017 | B2 |
| 9694361 | Bharadwaj | Jul 2017 | B2 |
| 9702004 | Van Eijk | Jul 2017 | B2 |
| 9714446 | Webster et al. | Jul 2017 | B2 |
| 9727810 | Fodor et al. | Aug 2017 | B2 |
| 9777324 | Van Eijk | Oct 2017 | B2 |
| 9783841 | Nolan et al. | Oct 2017 | B2 |
| 9834814 | Peter et al. | Dec 2017 | B2 |
| 9850536 | Oliphant et al. | Dec 2017 | B2 |
| 9868979 | Chee et al. | Jan 2018 | B2 |
| 9879313 | Chee et al. | Jan 2018 | B2 |
| 10002316 | Fodor et al. | Jun 2018 | B2 |
| 10023907 | Van Eijk | Jul 2018 | B2 |
| 10030261 | Frisen et al. | Jul 2018 | B2 |
| 10041949 | Bendall et al. | Aug 2018 | B2 |
| 10049770 | Madabhushi et al. | Aug 2018 | B2 |
| 10059990 | Boyden et al. | Aug 2018 | B2 |
| 10078895 | Madabhushi et al. | Sep 2018 | B2 |
| 10196691 | Harkin et al. | Feb 2019 | B2 |
| 10208982 | Bannish et al. | Feb 2019 | B2 |
| 10221461 | Robins et al. | Mar 2019 | B2 |
| 10246752 | Faham et al. | Apr 2019 | B2 |
| 10273541 | Hindson et al. | Apr 2019 | B2 |
| 10357771 | Bharadwaj | Jul 2019 | B2 |
| 10472669 | Chee | Nov 2019 | B2 |
| 10480022 | Chee | Nov 2019 | B2 |
| 10480029 | Bent et al. | Nov 2019 | B2 |
| 10494667 | Chee | Dec 2019 | B2 |
| 10550429 | Harada et al. | Feb 2020 | B2 |
| 10590244 | Delaney et al. | Mar 2020 | B2 |
| 10633648 | Seelig et al. | Apr 2020 | B2 |
| 10724078 | Van Driel et al. | Jul 2020 | B2 |
| 10725027 | Bell | Jul 2020 | B2 |
| 10774372 | Chee et al. | Sep 2020 | B2 |
| 10774374 | Frisen et al. | Sep 2020 | B2 |
| 10787701 | Chee | Sep 2020 | B2 |
| 10858702 | Lucero et al. | Dec 2020 | B2 |
| 10913975 | So et al. | Feb 2021 | B2 |
| 10914730 | Chee et al. | Feb 2021 | B2 |
| 10927403 | Chee et al. | Feb 2021 | B2 |
| 10961566 | Chee | Mar 2021 | B2 |
| 11008607 | Chee | May 2021 | B2 |
| 11046996 | Chee et al. | Jun 2021 | B1 |
| 11067567 | Chee | Jul 2021 | B2 |
| 11156603 | Chee | Oct 2021 | B2 |
| 11162132 | Frisen et al. | Nov 2021 | B2 |
| 11208684 | Chee | Dec 2021 | B2 |
| 11286515 | Chee et al. | Mar 2022 | B2 |
| 11293917 | Chee | Apr 2022 | B2 |
| 11299774 | Frisen et al. | Apr 2022 | B2 |
| 11313856 | Chee | Apr 2022 | B2 |
| 11332790 | Chell et al. | May 2022 | B2 |
| 11352659 | Frisen et al. | Jun 2022 | B2 |
| 11352667 | Hauling et al. | Jun 2022 | B2 |
| 11359228 | Chee et al. | Jun 2022 | B2 |
| 11365442 | Chee | Jun 2022 | B2 |
| 11371086 | Chee | Jun 2022 | B2 |
| 11384386 | Chee | Jul 2022 | B2 |
| 11390912 | Frisen et al. | Jul 2022 | B2 |
| 11401545 | Chee | Aug 2022 | B2 |
| 11407992 | Dadhwal | Aug 2022 | B2 |
| 11408029 | Katiraee et al. | Aug 2022 | B2 |
| 11434524 | Ramachandran Iyer et al. | Sep 2022 | B2 |
| 11479809 | Frisen et al. | Oct 2022 | B2 |
| 11479810 | Chee | Oct 2022 | B1 |
| 11492612 | Dadhwal | Nov 2022 | B1 |
| 11505828 | Chell et al. | Nov 2022 | B2 |
| 11512308 | Gallant et al. | Nov 2022 | B2 |
| 11519022 | Chee | Dec 2022 | B2 |
| 11519033 | Schnall-Levin et al. | Dec 2022 | B2 |
| 11530438 | Persson et al. | Dec 2022 | B2 |
| 11535887 | Gallant et al. | Dec 2022 | B2 |
| 11542543 | Chee | Jan 2023 | B2 |
| 11549138 | Chee | Jan 2023 | B2 |
| 11560587 | Chee | Jan 2023 | B2 |
| 11560592 | Chew et al. | Jan 2023 | B2 |
| 11560593 | Chell et al. | Jan 2023 | B2 |
| 11592447 | Uytingco et al. | Feb 2023 | B2 |
| 11608498 | Gallant et al. | Mar 2023 | B2 |
| 11608520 | Galonska et al. | Mar 2023 | B2 |
| 11613773 | Frisen et al. | Mar 2023 | B2 |
| 11618897 | Kim et al. | Apr 2023 | B2 |
| 11618918 | Chee et al. | Apr 2023 | B2 |
| 11624063 | Dadhwal | Apr 2023 | B2 |
| 11624086 | Uytingco et al. | Apr 2023 | B2 |
| 11634756 | Chee | Apr 2023 | B2 |
| 11649485 | Yin et al. | May 2023 | B2 |
| 11661626 | Katiraee et al. | May 2023 | B2 |
| 11680260 | Kim et al. | Jun 2023 | B2 |
| 11692218 | Engblom et al. | Jul 2023 | B2 |
| 11702693 | Bharadwaj | Jul 2023 | B2 |
| 11702698 | Stoeckius | Jul 2023 | B2 |
| 11732292 | Chee | Aug 2023 | B2 |
| 11732299 | Ramachandran Iyer | Aug 2023 | B2 |
| 11732300 | Bava | Aug 2023 | B2 |
| 11733238 | Chee | Aug 2023 | B2 |
| 11739372 | Frisen et al. | Aug 2023 | B2 |
| 11739381 | Chew et al. | Aug 2023 | B2 |
| 11753673 | Chew et al. | Sep 2023 | B2 |
| 11753674 | Chee et al. | Sep 2023 | B2 |
| 11753675 | Ramachandran Iyer | Sep 2023 | B2 |
| 11761030 | Chee | Sep 2023 | B2 |
| 11761038 | Stoeckius | Sep 2023 | B1 |
| 11767550 | Chee | Sep 2023 | B2 |
| 11768175 | Kim et al. | Sep 2023 | B1 |
| 11773433 | Gallant et al. | Oct 2023 | B2 |
| 11781130 | Dadhwal | Oct 2023 | B2 |
| 11788122 | Frisen et al. | Oct 2023 | B2 |
| 11795498 | Frisen et al. | Oct 2023 | B2 |
| 11795507 | Chell et al. | Oct 2023 | B2 |
| 11808769 | Uytingco et al. | Nov 2023 | B2 |
| 11821024 | Chee et al. | Nov 2023 | B2 |
| 11821035 | Bent et al. | Nov 2023 | B1 |
| 11827935 | Ramachandran Iyer et al. | Nov 2023 | B1 |
| 11835462 | Bava | Dec 2023 | B2 |
| 11840687 | Gallant et al. | Dec 2023 | B2 |
| 11840724 | Chew et al. | Dec 2023 | B2 |
| 11845979 | Engblom et al. | Dec 2023 | B2 |
| 11859178 | Gallant et al. | Jan 2024 | B2 |
| 11866767 | Uytingco et al. | Jan 2024 | B2 |
| 11866770 | Chee | Jan 2024 | B2 |
| 11873482 | Kim et al. | Jan 2024 | B2 |
| 11891654 | Alvarado Martinez et al. | Feb 2024 | B2 |
| 11898205 | Bava | Feb 2024 | B2 |
| 11926822 | Gohil et al. | Mar 2024 | B1 |
| 11926863 | Boutet | Mar 2024 | B1 |
| 11926867 | Yin et al. | Mar 2024 | B2 |
| 11933957 | Tentori et al. | Mar 2024 | B1 |
| 20020006477 | Shishido et al. | Jan 2002 | A1 |
| 20020040275 | Cravatt | Apr 2002 | A1 |
| 20020132246 | Kallioniemi et al. | Sep 2002 | A1 |
| 20020164611 | Bamdad | Nov 2002 | A1 |
| 20030017451 | Wang et al. | Jan 2003 | A1 |
| 20030022207 | Balasubramanian | Jan 2003 | A1 |
| 20030148335 | Shen et al. | Aug 2003 | A1 |
| 20030162216 | Gold | Aug 2003 | A1 |
| 20030170637 | Pirrung et al. | Sep 2003 | A1 |
| 20030211489 | Shen et al. | Nov 2003 | A1 |
| 20030224419 | Corcoran | Dec 2003 | A1 |
| 20030232348 | Jones et al. | Dec 2003 | A1 |
| 20030232382 | Brennan | Dec 2003 | A1 |
| 20040002090 | Mayer et al. | Jan 2004 | A1 |
| 20040019005 | Van Ness | Jan 2004 | A1 |
| 20040033499 | Ilsley et al. | Feb 2004 | A1 |
| 20040067492 | Peng et al. | Apr 2004 | A1 |
| 20040067493 | Matsuzaki | Apr 2004 | A1 |
| 20040096853 | Mayer | May 2004 | A1 |
| 20040106110 | Balasubramanian | Jun 2004 | A1 |
| 20050019776 | Callow et al. | Jan 2005 | A1 |
| 20050026188 | Van Kessel | Feb 2005 | A1 |
| 20050037362 | Remacle et al. | Feb 2005 | A1 |
| 20050037393 | Gunderson et al. | Feb 2005 | A1 |
| 20050048580 | Labaer | Mar 2005 | A1 |
| 20050100900 | Kawashima et al. | May 2005 | A1 |
| 20050130173 | Leamon et al. | Jun 2005 | A1 |
| 20050136414 | Gunderson et al. | Jun 2005 | A1 |
| 20050170373 | Monforte | Aug 2005 | A1 |
| 20050191656 | Drmanac et al. | Sep 2005 | A1 |
| 20050191698 | Chee et al. | Sep 2005 | A1 |
| 20050202433 | Van Beuningen | Sep 2005 | A1 |
| 20050227271 | Kwon | Oct 2005 | A1 |
| 20050260653 | LaBaer | Nov 2005 | A1 |
| 20060041385 | Bauer et al. | Feb 2006 | A1 |
| 20060110739 | Heyduk | May 2006 | A1 |
| 20060188875 | Cox et al. | Aug 2006 | A1 |
| 20060211001 | Yu et al. | Sep 2006 | A1 |
| 20060216775 | Burkart et al. | Sep 2006 | A1 |
| 20060228758 | Muchhal et al. | Oct 2006 | A1 |
| 20060263789 | Kincaid | Nov 2006 | A1 |
| 20070020640 | McCloskey et al. | Jan 2007 | A1 |
| 20070054288 | Su et al. | Mar 2007 | A1 |
| 20070099208 | Drmanac et al. | May 2007 | A1 |
| 20070128624 | Gormley et al. | Jun 2007 | A1 |
| 20070128656 | Agrawal | Jun 2007 | A1 |
| 20070161029 | Li et al. | Jul 2007 | A1 |
| 20070172873 | Brenner et al. | Jul 2007 | A1 |
| 20070178503 | Jiang | Aug 2007 | A1 |
| 20070207482 | Church et al. | Sep 2007 | A1 |
| 20070254305 | Paik et al. | Nov 2007 | A1 |
| 20070269805 | Hogers | Nov 2007 | A1 |
| 20080009420 | Schroth et al. | Jan 2008 | A1 |
| 20080108804 | Hayashizaki et al. | May 2008 | A1 |
| 20080153086 | Wong | Jun 2008 | A1 |
| 20080160580 | Adessi et al. | Jul 2008 | A1 |
| 20080220434 | Thomas | Sep 2008 | A1 |
| 20080261204 | Lexow | Oct 2008 | A1 |
| 20080286795 | Kawashima et al. | Nov 2008 | A1 |
| 20090005252 | Drmanac et al. | Jan 2009 | A1 |
| 20090006002 | Honisch et al. | Jan 2009 | A1 |
| 20090018024 | Church et al. | Jan 2009 | A1 |
| 20090026082 | Rothberg et al. | Jan 2009 | A1 |
| 20090082212 | Williams | Mar 2009 | A1 |
| 20090099041 | Church et al. | Apr 2009 | A1 |
| 20090105959 | Braverman et al. | Apr 2009 | A1 |
| 20090117573 | Fu et al. | May 2009 | A1 |
| 20090127589 | Rothberg et al. | May 2009 | A1 |
| 20090155781 | Drmanac et al. | Jun 2009 | A1 |
| 20090202998 | Schlumpberger et al. | Aug 2009 | A1 |
| 20090215633 | van Eijk et al. | Aug 2009 | A1 |
| 20090233802 | Bignell et al. | Sep 2009 | A1 |
| 20090253581 | van Eijk et al. | Oct 2009 | A1 |
| 20090270273 | Burns et al. | Oct 2009 | A1 |
| 20090291854 | Weisinger-Mayr et al. | Nov 2009 | A1 |
| 20090312193 | Kim et al. | Dec 2009 | A1 |
| 20100035249 | Hayashizaki et al. | Feb 2010 | A1 |
| 20100120097 | Matz et al. | May 2010 | A1 |
| 20100120098 | Grunenwald et al. | May 2010 | A1 |
| 20100145037 | Brive et al. | Jun 2010 | A1 |
| 20110028685 | Purkayastha et al. | Feb 2011 | A1 |
| 20110059436 | Hardin et al. | Mar 2011 | A1 |
| 20110111409 | Sinicropi et al. | May 2011 | A1 |
| 20110207134 | Faham et al. | Aug 2011 | A1 |
| 20110245111 | Chee | Oct 2011 | A1 |
| 20120135871 | van Eijk et al. | May 2012 | A1 |
| 20120202698 | van Eijk et al. | Aug 2012 | A1 |
| 20120202704 | Fan et al. | Aug 2012 | A1 |
| 20120252702 | Muratani et al. | Oct 2012 | A1 |
| 20130065768 | Zheng et al. | Mar 2013 | A1 |
| 20130171621 | Luo et al. | Jul 2013 | A1 |
| 20130202718 | Pepin et al. | Aug 2013 | A1 |
| 20130302801 | Asbury et al. | Nov 2013 | A1 |
| 20140066318 | Frisen et al. | Mar 2014 | A1 |
| 20140080715 | Lo et al. | Mar 2014 | A1 |
| 20140270435 | Dunn | Sep 2014 | A1 |
| 20140274731 | Raymond et al. | Sep 2014 | A1 |
| 20140296081 | Diehn et al. | Oct 2014 | A1 |
| 20140323330 | Glezer et al. | Oct 2014 | A1 |
| 20140378350 | Hindson et al. | Dec 2014 | A1 |
| 20150000854 | Gann-Fetter et al. | Jan 2015 | A1 |
| 20150051085 | Vogelstein et al. | Feb 2015 | A1 |
| 20150292988 | Bharadwaj et al. | Oct 2015 | A1 |
| 20150344942 | Frisen et al. | Dec 2015 | A1 |
| 20160108458 | Frei et al. | Apr 2016 | A1 |
| 20160138091 | Chee et al. | May 2016 | A1 |
| 20160145677 | Chee et al. | May 2016 | A1 |
| 20160253584 | Fodor et al. | Sep 2016 | A1 |
| 20160289740 | Fu et al. | Oct 2016 | A1 |
| 20160298180 | Chee | Oct 2016 | A1 |
| 20170016053 | Beechem et al. | Jan 2017 | A1 |
| 20170029875 | Zhang et al. | Feb 2017 | A1 |
| 20170067096 | Wassie et al. | Mar 2017 | A1 |
| 20170089811 | Tillberg et al. | Mar 2017 | A1 |
| 20170159109 | Zheng et al. | Jun 2017 | A1 |
| 20170220733 | Zhuang et al. | Aug 2017 | A1 |
| 20170241911 | Rockel et al. | Aug 2017 | A1 |
| 20170342405 | Fu et al. | Nov 2017 | A1 |
| 20180051322 | Church et al. | Feb 2018 | A1 |
| 20180057873 | Zhou et al. | Mar 2018 | A1 |
| 20180105808 | Mikkelsen et al. | Apr 2018 | A1 |
| 20180112209 | Eshoo | Apr 2018 | A1 |
| 20180112261 | Van Driel et al. | Apr 2018 | A1 |
| 20180156784 | Usmani et al. | Jun 2018 | A1 |
| 20180180601 | Pedersen et al. | Jun 2018 | A1 |
| 20180201980 | Chee et al. | Jul 2018 | A1 |
| 20180216161 | Chen et al. | Aug 2018 | A1 |
| 20180216162 | Belhocine et al. | Aug 2018 | A1 |
| 20180245142 | So et al. | Aug 2018 | A1 |
| 20180282803 | Belgrader et al. | Oct 2018 | A1 |
| 20180291439 | van Eijk et al. | Oct 2018 | A1 |
| 20180305681 | Jovanovich et al. | Oct 2018 | A1 |
| 20190055594 | Samusik et al. | Feb 2019 | A1 |
| 20190064173 | Bharadwaj et al. | Feb 2019 | A1 |
| 20190085383 | Church et al. | Mar 2019 | A1 |
| 20190161796 | Hauling et al. | May 2019 | A1 |
| 20190177777 | Chee | Jun 2019 | A1 |
| 20190177778 | Chee | Jun 2019 | A1 |
| 20190177789 | Hindson et al. | Jun 2019 | A1 |
| 20190177800 | Boutet et al. | Jun 2019 | A1 |
| 20190194709 | Church et al. | Jun 2019 | A1 |
| 20190203275 | Frisen et al. | Jul 2019 | A1 |
| 20190233878 | Delaney et al. | Aug 2019 | A1 |
| 20190249226 | Bent et al. | Aug 2019 | A1 |
| 20190262831 | West et al. | Aug 2019 | A1 |
| 20190264268 | Frisen et al. | Aug 2019 | A1 |
| 20190271030 | Chee | Sep 2019 | A1 |
| 20190271031 | Chee | Sep 2019 | A1 |
| 20190300943 | Chee et al. | Oct 2019 | A1 |
| 20190300944 | Chee et al. | Oct 2019 | A1 |
| 20190300945 | Chee et al. | Oct 2019 | A1 |
| 20190309353 | Chee | Oct 2019 | A1 |
| 20190309354 | Chee | Oct 2019 | A1 |
| 20190309355 | Chee | Oct 2019 | A1 |
| 20190323071 | Chee | Oct 2019 | A1 |
| 20190323088 | Boutet et al. | Oct 2019 | A1 |
| 20190330617 | Church et al. | Oct 2019 | A1 |
| 20190338353 | Belgrader et al. | Nov 2019 | A1 |
| 20190367969 | Belhocine et al. | Dec 2019 | A1 |
| 20190367982 | Belhocine et al. | Dec 2019 | A1 |
| 20190367997 | Bent et al. | Dec 2019 | A1 |
| 20200002763 | Belgrader et al. | Jan 2020 | A1 |
| 20200024641 | Nolan et al. | Jan 2020 | A1 |
| 20200047010 | Lee et al. | Feb 2020 | A1 |
| 20200048690 | Chee | Feb 2020 | A1 |
| 20200063191 | Kennedy-Darling et al. | Feb 2020 | A1 |
| 20200063195 | Chee | Feb 2020 | A1 |
| 20200063196 | Chee | Feb 2020 | A1 |
| 20200071751 | Daugharthy et al. | Mar 2020 | A1 |
| 20200080136 | Zhang et al. | Mar 2020 | A1 |
| 20200109443 | Chee | Apr 2020 | A1 |
| 20200173985 | Dong et al. | Jun 2020 | A1 |
| 20200224244 | Nilsson et al. | Jul 2020 | A1 |
| 20200239946 | Dewal | Jul 2020 | A1 |
| 20200256867 | Hennek et al. | Aug 2020 | A1 |
| 20200277663 | Iyer | Sep 2020 | A1 |
| 20200277664 | Frenz | Sep 2020 | A1 |
| 20200299757 | Chee et al. | Sep 2020 | A1 |
| 20200325531 | Chee | Oct 2020 | A1 |
| 20200370095 | Farmer et al. | Nov 2020 | A1 |
| 20200399687 | Frisen et al. | Dec 2020 | A1 |
| 20200407781 | Schnall-Levin | Dec 2020 | A1 |
| 20210010068 | Chee et al. | Jan 2021 | A1 |
| 20210010070 | Schnall-Levin et al. | Jan 2021 | A1 |
| 20210095331 | Fan et al. | Apr 2021 | A1 |
| 20210123040 | Macosko et al. | Apr 2021 | A1 |
| 20210140982 | Uytingco et al. | May 2021 | A1 |
| 20210150707 | Weisenfeld et al. | May 2021 | A1 |
| 20210155982 | Yin et al. | May 2021 | A1 |
| 20210158522 | Weisenfeld et al. | May 2021 | A1 |
| 20210172007 | Chee et al. | Jun 2021 | A1 |
| 20210189475 | Tentori et al. | Jun 2021 | A1 |
| 20210190770 | Delaney et al. | Jun 2021 | A1 |
| 20210198741 | Williams | Jul 2021 | A1 |
| 20210199660 | Williams et al. | Jul 2021 | A1 |
| 20210207202 | Chee | Jul 2021 | A1 |
| 20210214785 | Stoeckius | Jul 2021 | A1 |
| 20210222235 | Chee | Jul 2021 | A1 |
| 20210222241 | Bharadwaj | Jul 2021 | A1 |
| 20210222242 | Ramachandran Iyer | Jul 2021 | A1 |
| 20210222253 | Uytingco | Jul 2021 | A1 |
| 20210223227 | Stoeckius | Jul 2021 | A1 |
| 20210230584 | Mikkelsen et al. | Jul 2021 | A1 |
| 20210230681 | Patterson et al. | Jul 2021 | A1 |
| 20210230692 | Daugharthy et al. | Jul 2021 | A1 |
| 20210237022 | Bava | Aug 2021 | A1 |
| 20210238581 | Mikkelsen et al. | Aug 2021 | A1 |
| 20210238664 | Bava et al. | Aug 2021 | A1 |
| 20210238675 | Bava | Aug 2021 | A1 |
| 20210238680 | Bava | Aug 2021 | A1 |
| 20210247316 | Bava | Aug 2021 | A1 |
| 20210255175 | Chee et al. | Aug 2021 | A1 |
| 20210262018 | Bava et al. | Aug 2021 | A1 |
| 20210262019 | Alvarado Martinez et al. | Aug 2021 | A1 |
| 20210269864 | Chee | Sep 2021 | A1 |
| 20210270822 | Chee | Sep 2021 | A1 |
| 20210285036 | Yin et al. | Sep 2021 | A1 |
| 20210285046 | Chell et al. | Sep 2021 | A1 |
| 20210292748 | Frisen et al. | Sep 2021 | A1 |
| 20210292822 | Frisen et al. | Sep 2021 | A1 |
| 20210317510 | Chee et al. | Oct 2021 | A1 |
| 20210317524 | Lucero et al. | Oct 2021 | A1 |
| 20210324457 | Ramachandran Iyer et al. | Oct 2021 | A1 |
| 20210332424 | Schnall-Levin | Oct 2021 | A1 |
| 20210332425 | Pfeiffer et al. | Oct 2021 | A1 |
| 20210348221 | Chell et al. | Nov 2021 | A1 |
| 20220002791 | Frisen et al. | Jan 2022 | A1 |
| 20220003755 | Chee | Jan 2022 | A1 |
| 20220010367 | Ramachandran Iyer et al. | Jan 2022 | A1 |
| 20220017951 | Ramachandran Iyer et al. | Jan 2022 | A1 |
| 20220025446 | Shah | Jan 2022 | A1 |
| 20220025447 | Tentori et al. | Jan 2022 | A1 |
| 20220033888 | Schnall-Levin et al. | Feb 2022 | A1 |
| 20220049293 | Frenz et al. | Feb 2022 | A1 |
| 20220064630 | Bent et al. | Mar 2022 | A1 |
| 20220081728 | Williams | Mar 2022 | A1 |
| 20220090058 | Frisen et al. | Mar 2022 | A1 |
| 20220090175 | Uytingco et al. | Mar 2022 | A1 |
| 20220090181 | Gallant et al. | Mar 2022 | A1 |
| 20220098576 | Dadhwal | Mar 2022 | A1 |
| 20220098661 | Chew et al. | Mar 2022 | A1 |
| 20220106632 | Galonska et al. | Apr 2022 | A1 |
| 20220106633 | Engblom et al. | Apr 2022 | A1 |
| 20220112486 | Ramachandran Iyer et al. | Apr 2022 | A1 |
| 20220112545 | Chee | Apr 2022 | A1 |
| 20220119869 | Ramachandran Iyer et al. | Apr 2022 | A1 |
| 20220127659 | Frisen et al. | Apr 2022 | A1 |
| 20220127666 | Katiraee et al. | Apr 2022 | A1 |
| 20220127672 | Stoeckius | Apr 2022 | A1 |
| 20220145361 | Frenz et al. | May 2022 | A1 |
| 20220154255 | Chee et al. | May 2022 | A1 |
| 20220170083 | Khaled et al. | Jun 2022 | A1 |
| 20220195422 | Gallant et al. | Jun 2022 | A1 |
| 20220195505 | Frisen et al. | Jun 2022 | A1 |
| 20220196644 | Chee | Jun 2022 | A1 |
| 20220213526 | Frisen et al. | Jul 2022 | A1 |
| 20220220544 | Ach et al. | Jul 2022 | A1 |
| 20220241780 | Tentori et al. | Aug 2022 | A1 |
| 20220267844 | Ramachandran Iyer et al. | Aug 2022 | A1 |
| 20220282329 | Chell et al. | Sep 2022 | A1 |
| 20220290217 | Frenz et al. | Sep 2022 | A1 |
| 20220290219 | Chee | Sep 2022 | A1 |
| 20220298560 | Frisen et al. | Sep 2022 | A1 |
| 20220325325 | Chee et al. | Oct 2022 | A1 |
| 20220326251 | Uytingco et al. | Oct 2022 | A1 |
| 20220333171 | Chee | Oct 2022 | A1 |
| 20220333191 | Mikkelsen et al. | Oct 2022 | A1 |
| 20220333192 | Uytingco | Oct 2022 | A1 |
| 20220333195 | Schnall-Levin et al. | Oct 2022 | A1 |
| 20220334031 | Delaney et al. | Oct 2022 | A1 |
| 20220348905 | Dadhwal | Nov 2022 | A1 |
| 20220348992 | Stoeckius et al. | Nov 2022 | A1 |
| 20220356464 | Kim et al. | Nov 2022 | A1 |
| 20220364163 | Stahl et al. | Nov 2022 | A1 |
| 20220389491 | Chee | Dec 2022 | A1 |
| 20220389503 | Mikkelsen et al. | Dec 2022 | A1 |
| 20220389504 | Chew et al. | Dec 2022 | A1 |
| 20220403455 | Ramachandran Iyer et al. | Dec 2022 | A1 |
| 20220404245 | Chell et al. | Dec 2022 | A1 |
| 20230002812 | Stoeckius et al. | Jan 2023 | A1 |
| 20230014008 | Shastry | Jan 2023 | A1 |
| 20230416807 | Chee | Jan 2023 | A1 |
| 20230416808 | Sukovich et al. | Jan 2023 | A1 |
| 20230033960 | Gallant et al. | Feb 2023 | A1 |
| 20230034039 | Shahjamali | Feb 2023 | A1 |
| 20230034216 | Bava | Feb 2023 | A1 |
| 20230040363 | Chee | Feb 2023 | A1 |
| 20230042088 | Chee | Feb 2023 | A1 |
| 20230042817 | Mignardi | Feb 2023 | A1 |
| 20230047782 | Tentori et al. | Feb 2023 | A1 |
| 20230056549 | Dadhwal | Feb 2023 | A1 |
| 20230064372 | Chell et al. | Mar 2023 | A1 |
| 20230069046 | Chew et al. | Mar 2023 | A1 |
| 20230077364 | Patterson et al. | Mar 2023 | A1 |
| 20230080543 | Katiraee et al. | Mar 2023 | A1 |
| 20230081381 | Chew et al. | Mar 2023 | A1 |
| 20230100497 | Frisen et al. | Mar 2023 | A1 |
| 20230107023 | Chee | Apr 2023 | A1 |
| 20230111225 | Chew et al. | Apr 2023 | A1 |
| 20230113230 | Kim et al. | Apr 2023 | A1 |
| 20230126825 | Nagendran et al. | Apr 2023 | A1 |
| 20230129552 | Ramachandran Iyer | Apr 2023 | A1 |
| 20230135010 | Tentori et al. | May 2023 | A1 |
| 20230143569 | Iyer et al. | May 2023 | A1 |
| 20230145575 | Gallant et al. | May 2023 | A1 |
| 20230147726 | Hadrup et al. | May 2023 | A1 |
| 20230151412 | Chee | May 2023 | A1 |
| 20230159994 | Chee | May 2023 | A1 |
| 20230159995 | Iyer et al. | May 2023 | A1 |
| 20230160008 | Chell et al. | May 2023 | A1 |
| 20230175045 | Katsori et al. | Jun 2023 | A1 |
| 20230183785 | Frisen et al. | Jun 2023 | A1 |
| 20230194469 | Tentori et al. | Jun 2023 | A1 |
| 20230194470 | Kim et al. | Jun 2023 | A1 |
| 20230203478 | Kim et al. | Jun 2023 | A1 |
| 20230183684 | Gallant et al. | Jul 2023 | A1 |
| 20230212650 | Chew et al. | Jul 2023 | A1 |
| 20230212655 | Chee | Jul 2023 | A1 |
| 20230220368 | Kim | Jul 2023 | A1 |
| 20230220454 | Bent et al. | Jul 2023 | A1 |
| 20230220455 | Galonska et al. | Jul 2023 | A1 |
| 20230227811 | Dadhwal | Jul 2023 | A1 |
| 20230228762 | Uytingco et al. | Jul 2023 | A1 |
| 20230242973 | Frisen et al. | Aug 2023 | A1 |
| 20230242976 | Tentori et al. | Aug 2023 | A1 |
| 20230265488 | Gohil et al. | Aug 2023 | A1 |
| 20230265489 | Uytingco et al. | Aug 2023 | A1 |
| 20230265491 | Tentori et al. | Aug 2023 | A1 |
| 20230279474 | Katiraee | Sep 2023 | A1 |
| 20230279477 | Kvastad et al. | Sep 2023 | A1 |
| 20230279481 | Marrache et al. | Sep 2023 | A1 |
| 20230287399 | Gallant et al. | Sep 2023 | A1 |
| 20230287475 | Chell et al. | Sep 2023 | A1 |
| 20230287481 | Katsori et al. | Sep 2023 | A1 |
| 20230295699 | Sukovich et al. | Sep 2023 | A1 |
| 20230295722 | Bharadwaj | Sep 2023 | A1 |
| 20230304074 | Chee et al. | Sep 2023 | A1 |
| 20230304078 | Frisen et al. | Sep 2023 | A1 |
| 20230313279 | Giacomello et al. | Oct 2023 | A1 |
| 20230323340 | Dadhwal | Oct 2023 | A1 |
| 20230323434 | Yin et al. | Oct 2023 | A1 |
| 20230323436 | Chee | Oct 2023 | A1 |
| 20230323447 | Schnall-Levin et al. | Oct 2023 | A1 |
| 20230323453 | Stoeckius | Oct 2023 | A1 |
| 20230332138 | Kim et al. | Oct 2023 | A1 |
| 20230332211 | Chee | Oct 2023 | A1 |
| 20230332212 | Chew et al. | Oct 2023 | A1 |
| 20230332227 | Ramachandran Iyer | Oct 2023 | A1 |
| 20230332247 | Singh et al. | Oct 2023 | A1 |
| 20230358733 | Chee | Nov 2023 | A1 |
| 20230366008 | Chew et al. | Nov 2023 | A1 |
| 20230383285 | Kim et al. | Nov 2023 | A1 |
| 20230383344 | Stoeckius | Nov 2023 | A1 |
| 20230392204 | Chell et al. | Dec 2023 | A1 |
| 20230393071 | Bava | Dec 2023 | A1 |
| 20230407404 | Baumgartner et al. | Dec 2023 | A1 |
| 20230416850 | Singh et al. | Dec 2023 | A1 |
| 20240002931 | Bava | Jan 2024 | A1 |
| 20240011081 | Chee | Jan 2024 | A1 |
| 20240011090 | Chew et al. | Jan 2024 | A1 |
| 20240018572 | Mignardi | Jan 2024 | A1 |
| 20240018575 | Gallant et al. | Jan 2024 | A1 |
| 20240018589 | Schnall-Levin et al. | Jan 2024 | A1 |
| 20240026445 | Ramachandran Iyer et al. | Jan 2024 | A1 |
| 20240035937 | Cox et al. | Feb 2024 | A1 |
| 20240043908 | Chew et al. | Feb 2024 | A1 |
| 20240043925 | Bent et al. | Feb 2024 | A1 |
| 20240052343 | Gallant et al. | Feb 2024 | A1 |
| 20240053351 | Uytingco et al. | Feb 2024 | A1 |
| 20240060115 | Chee et al. | Feb 2024 | A1 |
| 20240067953 | Mikkelsen et al. | Feb 2024 | A1 |
| 20240068016 | Frisen et al. | Feb 2024 | A1 |
| 20240068017 | Lundeberg et al. | Feb 2024 | A1 |
| 20240076723 | Mignardi | Mar 2024 | A1 |
| 20240084365 | Frisen et al. | Mar 2024 | A1 |
| 20240084366 | Chee | Mar 2024 | A1 |
| 20240084383 | Ramachandran Iyer et al. | Mar 2024 | A1 |
| 20240093274 | Frisen et al. | Mar 2024 | A1 |
| 20240093290 | Stahl et al. | Mar 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 1680604 | Oct 2005 | CN |
| 108676814 | Oct 2018 | CN |
| 1923471 | May 2008 | EP |
| 2002017 | Dec 2008 | EP |
| 2881465 | Jun 2015 | EP |
| 3013984 | May 2016 | EP |
| 3511423 | Jul 2019 | EP |
| 3541956 | Sep 2019 | EP |
| 2145635 | Feb 2000 | RU |
| WO 1989010977 | Nov 1989 | WO |
| WO 1991006678 | May 1991 | WO |
| WO 1995025116 | Sep 1995 | WO |
| WO 1995035505 | Dec 1995 | WO |
| WO 2002059355 | Aug 2002 | WO |
| WO 2002077283 | Oct 2002 | WO |
| WO 2003002979 | Jan 2003 | WO |
| WO 2003010176 | Feb 2003 | WO |
| WO 2004055159 | Jul 2004 | WO |
| WO 2005007814 | Jan 2005 | WO |
| WO 2007073171 | Jun 2007 | WO |
| WO 2007076726 | Jul 2007 | WO |
| WO 2007145612 | Dec 2007 | WO |
| WO 2009032167 | Mar 2009 | WO |
| WO 2009152928 | Dec 2009 | WO |
| WO 2010053587 | May 2010 | WO |
| WO 2010126614 | Nov 2010 | WO |
| WO 2011008502 | Jan 2011 | WO |
| WO 2011068088 | Jun 2011 | WO |
| WO 2012083225 | Jun 2012 | WO |
| WO 2012140224 | Oct 2012 | WO |
| WO 2012159089 | Nov 2012 | WO |
| WO 2013033271 | Mar 2013 | WO |
| WO 2013090390 | Jun 2013 | WO |
| WO 2013123442 | Aug 2013 | WO |
| WO 2013131962 | Sep 2013 | WO |
| WO 2013138510 | Sep 2013 | WO |
| WO 2013150082 | Oct 2013 | WO |
| WO 2013150083 | Oct 2013 | WO |
| WO 2013155119 | Oct 2013 | WO |
| WO 2013158936 | Oct 2013 | WO |
| WO 2014060483 | Apr 2014 | WO |
| WO 2014144713 | Sep 2014 | WO |
| WO 2014210223 | Dec 2014 | WO |
| WO 2014210225 | Dec 2014 | WO |
| WO 2014210353 | Dec 2014 | WO |
| WO 2015031691 | Mar 2015 | WO |
| WO 2016138496 | Sep 2016 | WO |
| WO 2016138500 | Sep 2016 | WO |
| WO 2016166128 | Oct 2016 | WO |
| WO 2016168825 | Oct 2016 | WO |
| WO 2017019456 | Feb 2017 | WO |
| WO 2017075293 | May 2017 | WO |
| WO 2017096158 | Jul 2017 | WO |
| WO 2017177308 | Oct 2017 | WO |
| WO 2018064640 | Apr 2018 | WO |
| WO 2018075693 | Apr 2018 | WO |
| WO 2018085599 | May 2018 | WO |
| WO 2018091676 | May 2018 | WO |
| WO 2018175779 | Sep 2018 | WO |
| WO 2019213254 | Nov 2019 | WO |
| WO 2019213294 | Nov 2019 | WO |
| WO 2020028194 | Feb 2020 | WO |
| WO 2020047002 | Mar 2020 | WO |
| WO 2020047004 | Mar 2020 | WO |
| WO 2020047005 | Mar 2020 | WO |
| WO 2020047010 | Mar 2020 | WO |
| WO 2020053655 | Mar 2020 | WO |
| WO 2020061064 | Mar 2020 | WO |
| WO 2020061066 | Mar 2020 | WO |
| WO 2020061108 | Mar 2020 | WO |
| WO 2020076979 | Apr 2020 | WO |
| WO 2020099640 | May 2020 | WO |
| WO 2020123301 | Jun 2020 | WO |
| WO 2020123305 | Jun 2020 | WO |
| WO 2020123309 | Jun 2020 | WO |
| WO 2020123311 | Jun 2020 | WO |
| WO 2020123316 | Jun 2020 | WO |
| WO 2020123317 | Jun 2020 | WO |
| WO 2020123318 | Jun 2020 | WO |
| WO 2020123319 | Jun 2020 | WO |
| WO 2020123320 | Jul 2020 | WO |
| WO 2020142490 | Jul 2020 | WO |
| WO 2020160044 | Aug 2020 | WO |
| WO 2020167862 | Aug 2020 | WO |
| WO 2020176788 | Sep 2020 | WO |
| WO 2020176882 | Sep 2020 | WO |
| WO 2020190509 | Sep 2020 | WO |
| WO 2020198071 | Oct 2020 | WO |
| WO 2020206285 | Oct 2020 | WO |
| WO 2020219901 | Oct 2020 | WO |
| WO 2020243579 | Dec 2020 | WO |
| WO 2021041974 | Mar 2021 | WO |
| WO 2021067246 | Apr 2021 | WO |
| WO 2021067514 | Apr 2021 | WO |
| WO 2021091611 | May 2021 | WO |
| WO 2021092433 | May 2021 | WO |
| WO 2021097255 | May 2021 | WO |
| WO 2021102003 | May 2021 | WO |
| WO 2021102005 | May 2021 | WO |
| WO 2021102039 | May 2021 | WO |
| WO 2021116715 | Jun 2021 | WO |
| WO 2021133842 | Jul 2021 | WO |
| WO 2021133845 | Jul 2021 | WO |
| WO 2021133849 | Jul 2021 | WO |
| WO 2021142233 | Jul 2021 | WO |
| WO 2021168261 | Aug 2021 | WO |
| WO 2021168278 | Aug 2021 | WO |
| WO 2021207610 | Oct 2021 | WO |
| WO 2021216708 | Oct 2021 | WO |
| WO 2021225900 | Nov 2021 | WO |
| WO 2021236625 | Nov 2021 | WO |
| WO 2021236929 | Nov 2021 | WO |
| WO 2021237056 | Nov 2021 | WO |
| WO 2021237087 | Nov 2021 | WO |
| WO 2021242834 | Dec 2021 | WO |
| WO 2021247543 | Dec 2021 | WO |
| WO 2021247568 | Dec 2021 | WO |
| WO 2021252499 | Dec 2021 | WO |
| WO 2021252576 | Dec 2021 | WO |
| WO 2021252591 | Dec 2021 | WO |
| WO 2021252747 | Dec 2021 | WO |
| WO 2021263111 | Dec 2021 | WO |
| WO 2022025965 | Feb 2022 | WO |
| WO 2022060798 | Mar 2022 | WO |
| WO 2022060953 | Mar 2022 | WO |
| WO 2022061152 | Mar 2022 | WO |
| WO 2022087273 | Apr 2022 | WO |
| WO 2022099037 | May 2022 | WO |
| WO 2022103712 | May 2022 | WO |
| WO 2022109181 | May 2022 | WO |
| WO 2022132645 | Jun 2022 | WO |
| WO 2022140028 | Jun 2022 | WO |
| WO 2022147005 | Jul 2022 | WO |
| WO 2022147296 | Jul 2022 | WO |
| WO 2022164615 | Aug 2022 | WO |
| WO 2022178267 | Aug 2022 | WO |
| WO 2022198068 | Sep 2022 | WO |
| WO 2022221425 | Oct 2022 | WO |
| WO 2022226057 | Oct 2022 | WO |
| WO 2022236054 | Nov 2022 | WO |
| WO 2022243303 | Nov 2022 | WO |
| WO 2022226372 | Dec 2022 | WO |
| WO 2022256503 | Dec 2022 | WO |
| WO 2022271820 | Dec 2022 | WO |
| WO 2023287765 | Jan 2023 | WO |
| WO 2023018799 | Feb 2023 | WO |
| WO 2023034489 | Mar 2023 | WO |
| WO 2023076345 | May 2023 | WO |
| WO 2023086880 | May 2023 | WO |
| WO 2023102118 | Jun 2023 | WO |
| WO 2023150098 | Aug 2023 | WO |
| WO 2023150163 | Aug 2023 | WO |
| WO 2023150171 | Aug 2023 | WO |
| WO 2023215552 | Nov 2023 | WO |
| WO 2023225519 | Nov 2023 | WO |
| WO 2023229988 | Nov 2023 | WO |
| WO 2023250077 | Dec 2023 | WO |
| WO 2024015578 | Jan 2024 | WO |
| WO 2024035844 | Feb 2024 | WO |
| Entry |
|---|
| [No Author Listed], “Chromium Next GEM Single Cell 3′ Reagent Kits v3.1—User Guide,” 10x Genomics, Document No. CG000204, Nov. 2019, 58 pages. |
| [No Author Listed], “Chromium Next GEM Single Cell 3′ Reagent Kits v3.1 (Dual Index)—User Guide,” 10x Genomics, Mar. 2021, Document No. CG000315, 61 pages. |
| [No Author Listed], “HuSNP Mapping Assay User's Manual,” Affymetrix Part No. 90094 (Affymetrix, Santa Clara, Calif.), GeneChip, 2000, 104 pages. |
| [No Author Listed], “Microarray technologies have excellent possibilities in genomics-related researches,” Science Tools From Amersham Pharmacia Biotech, 1998, 3(4): 8 pages (with English Translation). |
| 10x Genomics, “Chromium Single Cell V(D)J Reagent Kits—User Guide,” 10x Genomics, 2018, CG000086 Rev J, 78 pages. |
| 10x Genomics, “Chromium Single Cell V(D)J Solution,” 10x Genomics, May 2017, 38 pages. |
| 10x Genomics, “Inside Visium Spatial Capture Technology,” 10x Genomics, 2021, 8 pages. |
| 10xGenomics.com, [online], “Visium Spatial Gene Expression Reagent Kits—Tissue Optimization—User Guide,” Jul. 2020, retrieved on May 25, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/5UJrNOCH17rEkOUXwd19It/e54d99fb08a8f1500aba503005a04a56/CG000238_VisiumSpatialTissueOptimizationUserGuide_RevD.pdf>, 42 pages. |
| 10xGenomics.com, [online], “Visium Spatial Gene Expression Reagent Kits—Tissue Optimization,” Nov. 2019, retrieved on Jan. 25, 2022, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/4q03w6959AJFxffSw5lee9/6a2ac61cf6388a72564eeb96bc294967/CG000238_VisiumSpatialTissueOptimizationUserGuide_Rev_A.pdf>, 46 pages. |
| 10xGenomics.com, [online], “Visium Spatial Gene Expression Reagent Kits—Tissue Optimization,” Oct. 2020, retrieved on Dec. 28, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/5UJrNOCH17rEkOUXwd19It/e54d99fb08a8f1500aba503005a04a56/CG000238_VisiumSpatialTissueOptimizationUserGuide_RevD.pdf>, 43 pages. |
| 10xGenomics.com, [online], “Visium Spatial Gene Expression Reagent Kits—User Guide,” Jun. 2020, retrieved on May 25, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/3GGIfH3RWpd1bFVhalpexR/8baa08d9007157592b65b2cdc7130990/CG000239_VisiumSpatialGeneExpression_UserGuide_RevD.pdf>, 69 pages. |
| 10xGenomics.com, [online], “Visium Spatial Gene Expression Reagent Kits—User Guide,” Oct. 2020, retrieved on Dec. 28, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/3GGIfH3RWpd1bFVhalpexR/8baa08d9007157592b65b2cdc7130990/CG000239_VisiumSpatialGeneExpression_UserGuide_RevD.pdf>, 70 pages. |
| Adessi et al., “Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms,” Nucl. Acids Res., 2000, 28(20):E87, 8 pages. |
| Adiconis et al., “Comparative analysis of RNA sequencing methods for degraded or low-input samples,” Nat Methods, Jul. 2013, 10(7):623-9. |
| Affymetrix, “GeneChip Human Genome U133 Set,” retrieved from the Internet: on the World Wide Web at affymetrix.com/support/technical/datasheets/hgu133_datasheet.pdf, retrieved on Feb. 26, 2003, 2 pages. |
| Affymetrix, “Human Genome U95Av2,” Internet Citation, retrieved from the internet: on the World Wide Web affymetrix.com, retrieved on Oct. 2, 2002, 1 page. |
| Akatsuka et al., “Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: Application for assessment of clonal composition,” Tissue Antigens, Jan. 5, 1999, 53:122-134. |
| Akatsuka et al., “T cell receptor clonal diversity following allogeneic marrow grafting,” Human Immunology, Jun.-Jul. 1996, 48:125-134. |
| Albretsen et al., “Applications of magnetic beads with covalently attached oligonucleotides in hybridization: Isolation and detection of specific measles virus mRNA from a crude cell lysate,” Anal. Biochem., 1990, 189(1):40-50. |
| Allawi et al., “Thermodynamics and NMR of Internal G.T Mismatches in DNA,” Biochemistry, 1996, 36(34):10581-10594. |
| Amgad et al., “Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group,” Nature Partner Journals Breast Cancer, May 2020, 6:16, 13 pages. |
| Andresen et al., “Deciphering the Antibodyome—Peptide Arrays for Serum Antibody Biomarker Diagnostics,” Current Proteomics, 6(1):1-12, 2009. |
| Armani et al, “2D-PCR: a method of mapping DNA in tissue sections,” Lab Chip, 2009, 9(24):3526-34. |
| Asp et al., “Spatial detection of fetal marker genes expressed at low level in adult human heart tissue,” Scientific Reports, 2017, 7(1):12941, 10 pages. |
| Asp et al., “Spatially Resolved Transcriptomes-Next Generation Tools for Tissue Exploration,” Bioessays, Oct. 2020, 42(10):e1900221, 16 pages. |
| Atkinson et al., “An Updated Protocol for High Throughput Plant Tissue Sectioning,” Front Plant Sci, 2017, 8:1721, 8 pages. |
| Atkinson, “Overview of Translation: Lecture Manuscript,” U of Texas, 2000, DD, p. 6.1-6.8. |
| Bains et al., “A novel method for nucleic acid sequence determination,” Journal of Theoretical Biology, 1988, 135(3), 303-7. |
| Baner et al., “Signal amplification of padlock probes by rolling circle replication,” Nucleic Acids Res., 1998, 26(22):5073-5078. |
| Barnes, “PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates,” Proc. Natl. Acad. Sci USA, 1994, 91(6):2216-2220. |
| Beattie et al., “Advances in genosensor research,” Clin Chem., May 1995, 41(5):700-6. |
| Beechem et al., “High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research,” Methods Mol Biol, 2020, Chapter 25, 2055:563-583. |
| Bentley et al., “Accurate whole human genome sequencing using reversible terminator chemistry,” Nature, 2008, 456(7218):53-59. |
| Bergenstråhle et al., “Seamless integration of image and molecular analysis for spatial transcriptomics workflows,” BMC Genomics, Jul. 2020, 21(1):482, 7 pages. |
| Bielas et al., “Human cancers express a mutator phenotype,” Proc. Natl. Acad. Sci. USA, 2006, 103(48): 18238-18242. |
| Birney et al., “Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project,” Nature, 2007, 447(7146):799-816. |
| Blanchard et al., “High-density oligonucleotide arrays,” Biosensors & Bioelectronics, 1996, 11(6-7):687-690. |
| Blandini et al., “Animal models of Parkinson's disease,” Febs J., Apr. 2012, 279(7):1156-66. |
| Blokzijl et al., “Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine,” J Intern. Med., 2010, 268(3):232-245. |
| Blow, “Tissue Issues,” Nature, 2007, 448(7156):959-962. |
| Bolotin et al., “MiXCR: software for comprehensive adaptive immunity profiling,” Nat Methods., May 2015, 12(5):380-1. |
| Borm et al., “High throughput human embryo spatial transcriptome mapping by surface transfer of tissue RNA,” Abstracts Selected Talks, Single Cell Genomics mtg, (SCG2019), 2019, 1 pages (Abstract Only). |
| Bowen et al., “Concurrent V(D)J recombination and DNA end instability increase interchromosomal trans-rearrangements in ATM-deficient thymocytes,” Nucleic Acids Research, Apr. 1, 2013, 41(8):4535-4548. |
| Bowtell, “The genesis and evolution of high-grade serous ovarian cancer,” Nat. Rev. Cancer, 2010, (11):803-808 Abstract. |
| Brandon et al., “Mitochondrial mutations in cancer,” Oncogene, 2006, 25(34):4647-4662. |
| Brenner et al., “Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays,” Nat. Biotech., 2000, 18(6):630-634. |
| Brenner et al., “In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs,” Proc. Natl. Acad. Sci. USA, 2000, 97(4):1665-1670. |
| Brow, “35—The Cleavase I enzyme for mutation and polymorphism scanning,” PCR Applications Protocols for Functional Genomics, 1999, pp. 537-550. |
| Brown et al., “Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein,” Proc Natl Acad Sci USA, Apr. 1989, 86(8):2525-9. |
| Buenrostro et al., “Transposition of native chromatin for multimodal regulatory analysis and personal epigenomics,” Nat Methods, Dec. 2013, 10(12):1213-1218. |
| Bullard et al., “Direct comparison of nick-joining activity of the nucleic acid ligases from bacteriophage T4,” Biochem. J. 2006, 398(1):135-144. |
| Burgess, “A space for transcriptomics,” Nature Reviews Genetics, 2016, 17(8):436-7. |
| Burgess, “Finding structure in gene expression,” Nature Reviews Genetics, 2018, 19(5):249, 1 page. |
| Burgess, “Spatial transcriptomics coming of age,” Nat Rev Genet., Jun. 2019, 20(6):317, 1 page. |
| Burton et al., “Coverslip Mounted-Immersion Cycled in Situ RT-PCR for the Localization of mRNA in Tissue Sections,” Biotechniques, 1998, 24(1):92-100. |
| Cerutti et al., “Generation of sequence-specific, high affinity anti-DNA antibodies,” Journal of Biological Chemistry, 2001, 276(16):12769-12773. |
| Cha et al., “Specificity, efficiency, and fidelity of PCR,” Genome Res., 1993, 3(3):S18-29. |
| Chandra et al., “Cell-free synthesis-based protein microarrays and their applications,” Proteomics, 2009, 5(6):717-30. |
| Chatterjee et al., “Mitochondrial DNA mutations in human cancer. Oncogene,” 2006, 25(34):4663-4674. |
| Chen et al., “A Homogeneous, Ligase-mediated DNA diagnostic test,” Genome research, 1998, 8(5):549-556. |
| Chen et al., “Large field of view-spatially resolved transcriptomics at nanoscale resolution,” bioRxiv, Jan. 19, 2021, retrieved from URL <https://www.biorxiv.org/node/1751045.abstract>, 37 pages. |
| Chen et al., “RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells,” Science, Apr. 2015, 348(6233):aaa6090, 21 pages. |
| Chen et al., “Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease,” Cell, Aug. 2020, 182(4):976-991. |
| Chen et al., “uCB-seq: microfluidic cell barcoding and sequencing for high-resolution imaging and sequencing of single cells,” Lab Chip, Nov. 2020, 20(21):3899-3913. |
| Cho et al., “Seq-Scope: Submicrometer-resolution spatial transcriptomics for single cell and subcellular studies,” bioRxiv, Jan. 27, 2021, retrieved from URL <https://www.biorxiv.org/node/1754517.abstract>, 50 pages. |
| Codeluppi et al., “Spatial organization of the somatosensory cortex revealed by osmFISH,” Nature Methods, Nov. 2018, 15:932-935. |
| Cole et al., “Complete characterization of the human immune cell transcriptome using accurate full-length cDNA sequencing,” Genome Research, Apr. 2020, 30:589-601. |
| Constantine et al., “Use of genechip high-density oligonucleotide arrays for gene expression monitoring,” Life Science News, Amersham Life Science, 1998, pp. 11-14. |
| Copeland et al., “Mitochondrial DNA Alterations in Cancer,” Cancer Invest., 2002, 557-569. |
| Credle et al., “Multiplexed analysis of fixed tissue RNA using Ligation in situ Hybridization,” Nucleic Acids Research, 2017, 45(14):e128, 9 pages. |
| Crosetto et al., “Spatially resolved transcriptomics and beyond,” Nature Review Genetics, 2015, 16(1):57-66. |
| Czarnik, “Encoding methods for combinatorial chemistry,” Curr Opin Chem Biol., Jun. 1997, 1(1):60-6. |
| Dahl et al., “Circle-to-circle amplification for precise and sensitive DNA analysis,” Proc. Natl. Acad. Sci., 2004, 101(13):4548-4553. |
| Dalma-Weiszhausz et al., “The affymetrix GeneChip platform: an overview,” Methods Enzymol., 2006, 410:3-28. |
| Daubendiek et al., “Rolling-Circle RNA Synthesis: Circular Oligonucleotides as Efficient Substrates for T7 RNA Polymerase,” J. Am. Chem. Soc., 1995, 117(29):7818-7819. |
| Davies et al., “How best to identify chromosomal interactions: a comparison of approaches,” Nat. Methods, 2017, 14(2):125-134. |
| Davis et al., “Recent progress in the analysis of αβ T cell and B cell receptor repertoires,” Current Opinion in Immunology, Aug. 2019, 59:109-114. |
| Dawson et al., “Animal models of neurodegenerative diseases,” Nat Neurosci., Oct. 2018, 21(10):1370-1379. |
| Dawson et al., “Genetic animal models of Parkinson's disease,” Neuron, Jun. 2010, 66(5):646-661. |
| Dean et al., “Comprehensive human genome amplification using multiple displacement amplification,” Proc Natl. Acad. Sci. USA, 2002, 99(8):5261-66. |
| Dean et al., “Rapid Amplification Of Plasmid And Phage DNA Using Phi29 DNA Polymerase And Multiply-Primed Rolling Circle Amplification,” Genome Research, Jun. 2001, 11:1095-1099. |
| Deng et al., “Spatial Epigenome Sequencing at Tissue Scale and Cellular Level,” BioRxiv, Mar. 2021, 40 pages. |
| Drmanac et al., “Accurate sequencing by hybridization for DNA diagnostics and individual genomics,” Nature Biotechnology, 16:54-58, 1998. |
| Duncan et al., “Affinity chromatography of a sequence-specific DNA binding protein using Teflon-linked oligonucleotides,” Anal. Biochem., 1988, 169(1):104-108. |
| Eagen, “Principles of Chromosome Architecture Revealed by Hi-C,” Trends in Biochemical Sciences, Jun. 2018, 43(6):469-478. |
| Efremova et al., “Immunology in the Era of Single-Cell Technologies,” Annu Rev Immunol., Apr. 2020, 38:727-757. |
| Eguiluz et al., “Multitissue array review: a chronological description of tissue array techniques, applications and procedures,” Pathology Research and Practice, 2006, 202(8):561-568. |
| Eldridge et al., “An in vitro selection strategy for conferring protease resistance to ligand binding peptides,” Protein Eng Des Sel., 2009, 22(11):691-698. |
| Ellington et al., “Antibody-based protein multiplex platforms: technical and operational challenges,” Clin Chem, 2010, 56(2):186-193. |
| Eng et al., “Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH+,” Nature, Apr. 2019, 568(7751):235-239, 37 pages. |
| Fan et al., “Single-cell RNA-seq and V(D)J profiling of immune cells in COVID-19 patients,” medRxiv, May 27, 2020, 35 pages. |
| Faruqi et al., “High-throughput genotyping of single nucleotide polymorphisms with rolling circle amplification,” BMC Genomics, Aug. 2001, 2:4, 10 pages. |
| Fire et al., “Rolling replication of short DNA circles,” Proc. Natl. Acad. Sci., 1995, 92(10):4641-4645. |
| Fluidigm, “Hyperion Imaging System: Visualize a new path forward,” Feb. 2018, retrieved from URL <https://www.fluidigm.com/binaries/content/documents/fluidigm/search/hippo%3Aresultset/hyperion-imaging-system-br-400326/fluidigm%3Afile>, 27 pages. |
| Fluidigm, “Immuno-Oncology Research with the Hyperion Imaging System: A high-parameter imaging solution at subcellular resolution to characterize the immune repertoire in the tumor microenvironment,” Apr. 2018, retrieved from URL <https://www.fluidigm.com/binaries/content/documents/fluidigm/search/hippo%3Aresultset/application-note-immuno-oncology-research-with-the-hyperion%E2%84%A2-imaging-system/fluidigm%3Afile>, 6 pages. |
| Fluidigm, “Immuno-Oncology Research with the Hyperion Imaging System: A high-parameter imaging solution at subcellular resolution to characterize the immune repertoire in the tumor microenvironment,” Aug. 2018, retrieved from URL <https://www.fluidigm.com/binaries/content/documents/fluidigm/marketing/immuno-oncology-research-with-the-hyperion-imaging-system-appnote-400332/immuno-oncology-research-with-the-hyperion-imaging-system-appnote-400332/fluidigm%3Afile>, 6 pages. |
| Fluidigm, “Maxpar Antibodies for Imaging Mass Cytometry,” Mar. 2018, retrieved from URL <https://www.fluidigm.com/binaries/content/documents/fluidigm/search/hippo%3Aresultset/hyperion-antibodies-for-imaging-mass-cytometry-br-101-7115/fluidigm%3Afile>, 2 pages. |
| Fodor et al., “Light-directed, spatially addressable parallel chemical synthesis,” Science, 1995, 251(4995):767-773. |
| Forster et al., “A human gut bacterial genome and culture collection for improved metagenomic analyses,” Nature Biotechnology, 2019, 37(2):186-192. |
| Fredriksson et al., “Multiplexed protein detection by proximity ligation for cancer detection,” Nature Methods, 4(4): 327-29, 2007. |
| Fredriksson et al., “Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer,” Clin. Chem., 5(3): 582-89, 2008. |
| Frese et al., “Formylglycine aldehyde Tag-protein engineering through a novel post-translational modification,” ChemBioChem., 2009, 10(3):425-27. |
| Fu et al., “Continuous Polony Gels for Tissue Mapping with High Resolution and RNA Capture Efficiency,” bioRxiv, 2021, 20 pages. |
| Fu et al., “Counting individual DNA molecules by the stochastic attachment of diverse labels,” PNAS, 2011, 108(22):9026-9031. |
| Fullwood et al., “Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses,” Genome Res., 2009, 19(4):521-532. |
| Ganguli et al., “Pixelated spatial gene expression analysis from tissue,” Nat Commun., Jan. 2018, 9(1):202, 9 pages. |
| Gao et al., “Q&A: Expansion microscopy,” BMC Biology, 15:50, 9 pages, 2017. |
| GenBank Accession No. M10098.1, “Human 18S rRNA gene, complete,” Aug. 3, 1993, 2 pages. |
| GenBank Accession No. M11167.1, “Human 28S ribosomal RNA gene,” Aug. 3, 1993, 2 pages. |
| Gene@arrays[online], BeadArray Technology, available on or before Feb. 14, 2015, via Internet Archive: Wayback Machine URL <https://web.archive.org/web/20150214084616/http://genearrays.com/services/microarrays/illumina/beadarray-technology/>, [retrieved on Jan. 30, 2020], 3 pages. |
| Giacomello et al., “Spatially resolved transcriptome profiling in model plant species”, Nature Plants 3, 17061, 11 pages, 2017. |
| Gibson et al., “Enzymatic assembly of DNA molecules up to several hundred kilobases,” Nat Methods., May 2009, 6(5):343-5. |
| Gilar et al., “Study of phosphorothioate-modified oligonucleotide resistance to 3′-exonuclease using capillary electrophoresis,” J Chromatogr B Biomed Sci Appl., Aug. 28, 1998, 714(1):13-20. |
| Gilles et al., “Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips,” Nat Biotechnol, Apr. 1999, 17(4):365-70. |
| Gnanapragasam, “Unlocking the molecular archive: the emerging use of formalin-fixed paraffin-embedded tissue for biomarker research in urological cancer,” BJU International, 2009, 105(2):274-278. |
| Goh et al., “Highly Specific Multiplexed RNA Imaging In Tissues With Split-FISH,” Nat Methods, Jun. 15, 2020, 17(7):689-693, 21 pages. |
| Goldkorn et al., “A simple and efficient enzymatic method for covalent attachment of DNA to cellulose. Application for hybridization-restriction analysis and for in vitro synthesis of DNA probes,” Nucleic Acids Res., 1986, 14(22):9171-9191. |
| Goltsev et al., “Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging,” Cell, 2018, 174(4):968-981. |
| Goransson et al., “A single molecule array for digital targeted molecular analyses,” Nucleic Acids Res., Nov. 25, 2009, 37(1):e7, 9 pages. |
| Gracia Villacampa et al., “Genome-wide Spatial Expression Profiling in FFPE Tissues,” bioRxiv, 2020, pp. 38 pages. |
| Gunderson et al., “Decoding randomly ordered DNA arrays,” Genome Research, 2004, 14(5):870-877. |
| Guo et al., “Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports,” Nucleic Acids Res., Dec. 1994, 22(24):5456-65. |
| Gupta et al., “Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells,” Nature Biotechnol., Oct. 2018, 36:1197-1202. |
| Hadley et al., “Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics,” ELIFE, 2015, 4(e09579):21 pages. |
| Hamaguchi et al., “Direct reverse transcription-PCR on oligo(dT)-immobilized polypropylene microplates after capturing total mRNA from crude cell lysates,” Clin Chem., Nov. 1998, 44(11):2256-63. |
| Han et al., “3C and 3C-based techniques: the powerful tools for spatial genome organization deciphering”, Molecular Cytogenetics (2018) 11: 21, 10 pages, 2018. |
| Hayes et al., “Electrophoresis of proteins and nucleic acids: I-Theory,” BMJ, Sep. 1989, 299(6703):843-6. |
| He et al., “In situ synthesis of protein arrays,” Current Opinion in Biotechnology, 2008, 19(1):4-9. |
| He, “Cell-free protein synthesis: applications in proteomics and biotechnology,” New Biotechnology, 2008, 25(2-3):126-132. |
| Heather et al., “High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities,” Briefings in Bioinformatics, 2018, 19(4):554-565. |
| Hejatko et al., “In situ hybridization technique for mRNA detection in whole mount Arabidopsis samples,” Nature Protocols, 2006, 1(4):1939-1946. |
| Hiatt et al., “Parallel, tag-directed assembly of locally derived short sequence reads,” Nature Methods, 2010, 7(2):119-25. |
| Hlubek et al., “Heterogeneous expression of Wnt/b-catenin target genes within colorectal cancer,” 2007, Int. J. Cancer: 2017, 1941-1948. |
| Hou et al., “Basic research and clinical application of immune repertoire sequencing,” Int J Clin Exp Med., Oct. 30, 2016, 9(10):18868-18882. |
| Hudson et al., “Localization of T cell clonotypes using the Visium spatial transcriptomics platform,” STAR Protocols, Jun. 17, 2022, 3:101391, 14 pages. |
| Inoue and Wittbrodt, “One for All—A Highly Efficient and Versatile Method for Fluorescent Immunostaining in Fish Embryos,” PLoS One 6, e19713, 2011. |
| Jamur et al., “Permeabilization of cell membranes.,” Method Mol. Biol., 2010, 588:63-66. |
| Jemt et al., “An automated approach to prepare tissue-derived spatially barcoded RNA-sequencing libraries,” Scientific Reports, 2016, 6:37137, 10 pages. |
| Kapteyn et al., “Incorporation of non-natural nucleotides into template-switching oligonucleotides reduces background and improves cDNA synthesis from very small RNA samples,” BMC Genomics, Jul. 2010, 11:413, 9 pages. |
| Kim et al., “Deep sequencing of B cell receptor repertoire,” BMB Rep., Sep. 30, 2019, 52(9):540-547. |
| Kolovos et al., “Investigation of the spatial structure and interactions of the genome at sub-kilobasepair resolution using T2C,” Nat. Protoc., 2018, 13:459-477. |
| Korbel et al., “Paired-end mapping reveals extensive structural variation in the human genome,” Science, 2007, 318(5849):420-426. |
| Kozlov et al., “A highly scalable peptide-based assay system for proteomics,” PLoS ONE, 2012, 7(6):e37441, 10 pages. |
| Kristensen et al., “High-Throughput Methods for Detection of Genetic Variation,” BioTechniques, Feb. 2001, 30(2):318-332. |
| Kurz et al., “cDNA-protein fusions: covalent protein-gene conjugates for the in vitro selection of peptides and proteins,” ChemBioChem., 2001, 2(9):666-72. |
| Kwok, “High-throughput genotyping assay approaches,” Pharmocogenomics, Feb. 2000, 1(1):95-100. |
| Lage et al., “Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH,” Genome Research, 2003, 13(2):294-307. |
| Landegren et al., “Reading bits of genetic information: methods for single-nucleotide polymorphism analysis,” Genome Res., Aug. 1998, 8(8):769-76. |
| Langdale et al., “A rapid method of gene detection using DNA bound to Sephacryl,” Gene, 1985, 36(3):201-210. |
| Larman et al., “Autoantigen discovery with a synthetic human peptidome,” Nature Biotechnology, May 2011, 29(6):535-541. |
| Lassmann et al., A Novel Approach For Reliable Microarray Analysis of Microdissected Tumor Cells From Formalin-Fixed and Paraffin-Embedded Colorectal Cancer Resection Specimens, J Mol Med, 87, 211-224, 2009. |
| Lee et al., “Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues,” Nature Protocols, 2015, 10(3):442-458. |
| Lee et al., “Identifying T Cell Receptors from High-Throughput Sequencing: Dealing with Promiscuity in TCRα and TCRβ Pairing,” PLoS Comput Biol., Jan. 2017, 13(1):e1005313, 25 pages. |
| Lein et al., “The promise of spatial transcriptomics for neuroscience in the era of molecular cell typing”, Science 358, 64-69, 2017. |
| Leriche et al., “Cleavable linkers in chemical biology,” Bioorganic & Medicinal Chemistry, 2012, 20:571-582. |
| Lewczuk et al., “Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry,” World J Biol Psychiatry, Jun. 2018, 19(4):244-328. |
| Li et al., “RNase H-dependent PCR-enabled T-cell receptor sequencing for highly speci!c and ef!cient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis,” Nature Protocols, Aug. 2019, 14:2571-2594. |
| Linnarsson, “Recent advances in DNA sequencing methods—general principles of sample preparation,” Experimental Cell Research, 2010, 316(8):1339-1343. |
| Liu et al., “High-Spatial-Resolution Multi-Omics Atlas Sequencing of Mouse Embryos via Deterministic Barcoding in Tissue,” BioRxiv, 2019, 55 pages. |
| Liu et al., “High-Spatial-Resolution Multi-Omics Sequencing via Deterministic Barcoding in Tissue,” Cell, Nov. 13, 2020, 183(6):1665-1681, 36 pages. |
| Liu et al., “Spatial transcriptome sequencing of FFPE tissues at cellular level,” bioRxiv 788992, Oct. 14, 2020, 39 pages. |
| Lizardi et al., “Mutation detection and single-molecule counting using isothermal rolling-circle amplification,” Nat. Genet., 1998, 19(3):225-232. |
| Lovatt et al., “Transcriptome in vivo analysis (TIVA) of spatially defined single cells in live tissue,” Nature Methods, 2013, 11(2):190-196. |
| Lundberg et al., “Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material,” Mol Cell Proteomics, 2011, 10(4):M110.004978, 11 pages. |
| Luo et al., “Probing infectious disease by single-cell RNA sequencing: Progresses and perspectives,” Computational and Structural Biotechnology Journal, Oct. 21, 2020, 18:2962-2971. |
| MacBeath et al., “Printing proteins as microarrays for high-throughput function determination,” Science, Sep. 2000, 289(5485):1760-1763. |
| Mamedov et al., “Preparing unbiased T-cell receptor and antibody cDNA libraries for the deep next generation sequencing profiling,” Frontiers in Immunol., Dec. 23, 2013, 4(456):1-10. |
| Maniatis et al., “Spatiotemporal Dynamics of Molecular Pathology in Amyotrophic Lateral Sclerosis”, 54 pages, 2018. |
| Martin, “Cutadapt removes adapter sequences from high-throughput sequencing reads,” EMBnet Journal, 2011, 17(1):10-12. |
| Marx, “Method of the Year: spatially resolved transcriptomics,” Nature Methods, 2021, 18(1):9-14. |
| McKernan et al., “Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding,” Genome Res., 19: 1527-41, 2009. |
| Merritt et al., “Multiplex digital spatial profiling of proteins and RNA in fixed tissue,” Nat Biotechnol, May 2020, 38(5):586-599. |
| Metzker, “Sequencing technologies—the next generation,” Nature Reviews Genetics, 2010, 11(1):31-46. |
| Miller et al., “Basic concepts of microarrays and potential applications in clinical microbiology,” Clinical Microbiology Reviews, 2009, 22(4):611-633. |
| Miller et al., “Chapter 11—Solid and Suspension Microarrays for Microbial Diagnostics,” Methods in Microbiology, 2015, 42:395-431. |
| Mishra et al., “Three-dimensional genome architecture and emerging technologies: looping in disease,” Genome Medicine, 2017, 9(1):87, 14 pages. |
| Mitra et al., “Digital genotyping and haplotyping with polymerase colonies,” Proc. Natl. Acad. Sci. USA, May 2003, 100(10):5926-5931. |
| Mizusawa et al., “A bacteriophage lambda vector for cloning with BamHI and Sau3A,” Gene, 1982, 20(3):317-322. |
| Mohsen et al., “The Discovery of Rolling Circle Amplification and Rolling Circle Transcription,” Acc Chem Res., Nov. 15, 2016, 49(11):2540-2550, 25 pages. |
| Moncada et al., “Building a tumor atlas: integrating single-cell RNA-Seq data with spatial transcriptomics in pancreatic ductal adenocarcinoma”, Institute for Computational Medicine, bioRxiv, 28 p. 2018. |
| Moor et al., “Spatial transcriptomics: paving the way for tissue-level systems biology”, Science Direct, Current Opinion in Biotechnology, 46: 126-133, 2017. |
| Morlan et al., “Selective depletion of rRNA enables whole transcriptome profiling of archival fixed tissue,” PLoS One, Aug. 2012, 7(8):e42882, 8 pages. |
| Mortazavi et al., “Mapping and quantifying mammalian transcriptomes by RNA-Seq,” Nature Methods, 5(7): 621-8, 2008. |
| Mulder et al., “CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling,” Blood Advances, Dec. 2018, 2(23):3506-3514. |
| Nagahara et al., “Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease,” Nat Med., Mar. 2009, 15(3):331-337. |
| Nam et al., “Somatic mutations and cell identity linked by Genotyping of Transcriptomes,” Nature, Jul. 2019, 571(7765):355-360. |
| Ncbi.nlm.nih.gov, [online], “Molecular Inversion Probe Assay,” available on or before Oct. 14, 2014, via Internet Archive: Wayback Machine URL<https://web.archive.org/web/20141014124037/https://www.ncbi.nlm.nih.gov/probe/docs/techmip/>, retrieved on Jun. 16, 2021, retrieved from URL<https://www.ncbi.nlm.nih.gov/probe/docs/techmip/>, 2 pages. |
| Ng et al., “Massively parallel sequencing and rare disease,” Human Malec. Genetics, 19(2): R119-R124, 2010. |
| Ng et al., “Multiplex sequencing of paired-end ditags (MS-PET): a strategy for the ultra-high-throughput analysis of transcriptomes and genomes,” Nucleic Acids Research, Jul. 2006, 34(12): e84, 10 pages. |
| Nikiforov et al., “The use of 96-well polystyrene plates for DNA hybridization-based assays: an evaluation of different approaches to oligonucleotide immobilization,” Anal Biochem, May 1995, 227(1):201-9. |
| Nowak et al., “Entering the Postgenome Era,” Science, 1995, 270(5235):368-71. |
| Park et al., “The Estimation of Breast Cancer Disease—Probability by Difference of Individual Susceptibility,” Cancer Res. Treat., Feb. 2003, 35(1):35-51, Abstract. |
| Pasetto et al., “Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy,” Frontiers in Immunology, Jun. 7, 2021, 12:689091, 12 pages. |
| Paterson et al., “Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic,” Alzheimers Res Ther., Mar. 2018, 10(1):32, 11 pages. |
| PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2021/035211, dated Dec. 6, 2022, 17 pages. |
| PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2021/035242, dated Dec. 6, 2022, 7 pages. |
| PCT International Search Report and Written Opinion in International Appln. No. PCT/US2021/035211, dated Sep. 30, 2021, 27 pages. |
| PCT International Search Report and Written Opinion in International Appln. No. PCT/US2021/035242, dated Sep. 2, 2021, 13 pages. |
| PCT Invitation to Pay Additional Fees in International Appln. No. PCT/US2021/035211, dated Oct. 12, 2021, 17 pages. |
| Pemov et al., “DNA analysis with multiplex microarray-enhanced PCR,” Nucl. Acids Res., Jan. 2005, 33(2):e11, 9 pages. |
| Perler et al., “Intervening sequences in an Archaea DNA polymerase gene,” Proc Natl Acad Sci USA, Jun. 1992, 89(12):5577-5581. |
| Petterson et al., “Generations of sequencing technologies,” Genomics, 2009, 93(2):105-111. |
| Picelli et al., “Full-length RNA-seq from single cells using Smart-seq2,” Nat Protoc., Jan. 2014, 9(1):171-81. |
| Polsky-Cynkin et al., “Use of DNA immobilized on plastic and agarose supports to detect DNA by sandwich hybridization,” Clin. Chem., 1985, 31(9):1438-1443. |
| U.S. Appl. No. 61/267,363, filed Dec. 7, 2009, 33 pages. |
| Raj et al., “Imaging individual mRNA molecules using multiple singly labeled probes,” Nature Methods, Oct. 2008, 5(10):877-879, 9 pages. |
| Rajeswari et al., “Multiple pathogen biomarker detection using an encoded bead array in droplet PCR,” J. Microbial Methods, Aug. 2017, 139:22-28. |
| Ranki et al., “Sandwich hybridization as a convenient method for the detection of nucleic acids in crude samples,” Gene, 1983, 21(1-2):77-85. |
| Ranzoni et al., “Application of single-cell RNA sequencing methodologies in understanding haematopoiesis and immunology,” Essays in Biochemistry, Jul. 3, 2019, 63:217-225. |
| Reinartz et al., “Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms,” Brief Funct Genomic Proteomic, Feb. 2002, 1(1):95-104. |
| Robins et al., “Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells,” Blood, Nov. 5, 2009, 114(19):4099-4107. |
| Rodriques et al., “Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution,” Science, 2019, 363(6434):1463-1467. |
| Ronaghi et al., “A sequencing method based on real-time pyrophosphate,” Science, Jul. 1998, 281(5375):363-365. |
| Ronaghi et al., “Real-time DNA sequencing using detection of pyrophosphate release,” Analytical Biochemistry, Nov. 1996, 242(1):84-89. |
| Ronaghi, “Pyrosequencing sheds light on DNA sequencing,” Genome Res, Jan. 2001, 11(1):3-11. |
| Rubin et al., “Whole-genome resequencing reveals loci under selection during chicken domestication.,” Nature, Mar. 2010, 464: 587-591. |
| Salmén et al., “Barcoded solid-phase RNA capture for Spatial Transcriptomics profiling in mammalian tissue sections,” Nature Protocols, Oct. 2018, 13(11):2501-2534. |
| Salmen et al., “Multidimensional transcriptomics provides detailed information about immune cell distribution and identity in HER2+ breast tumors,” bioRxiv, 2018, 41 pages. |
| Saxonov et al., “10x Genomics, Mastering Biology to Advance Human Health,” PowerPoint, 10x, 2020, 41 pages. |
| Scheideler et al., “Recapitulating complex biological signaling environments using a multiplexed, DNA-patterning approach,” Sci. Adv., 2020, 6:eay5696. |
| Schena et al., “Quantitative monitoring of gene expression patterns with a complementary DNA microarray,” Science, Oct. 1995, 270(5235):467-470. |
| Schmitt et al., “Detection of ultra-rare mutations by next-generation sequencing,” PNAS (2012) 109:14508-14523. |
| Schweitzer et al., “Immunoassays with rolling circle DNA amplification: A versatile platform for ultrasensitive antigen detection,” Proc. Natl Acad. Sci. USA, May 22, 2000, 97:10113-119. |
| Segaliny et al., “Functional TCR T cell screening using single-cell droplet microfluidicst,” Lab Chip, 2018, 3733-3749. |
| Sergeeva et al., “Display technologies: Application for the discovery of drug and gene delivery agents,” Advanced Drug Delivery Reviews, 2006, 58(15):1622-1654. |
| Shalon et al., “A Dna microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization,” Genome Res., Jul. 1996, 6(7):639-45. |
| Sheth et al., “Spatial metagenomic characterization of microbial biogeography in the gut,” Nature Biotechnology, Aug. 2019, 37:877-883. |
| Shi, “Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies,” Clin. Chem., Feb. 2001, 47(2):164-172. |
| Shoemaker et al., “Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy,” Nature genetics (1996) 14:450-456. |
| Sievertzon et al., “Transcriptome analysis in primary neural stem cells using a tag cDNA amplification method,” BMC Neuroscience, Dec. 2005, 6: 28. |
| Singh et al., “High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes,” Nat Commun., Jul. 2019, 10(1):3120, 13 pages. |
| Stahl et al., “Visualization and analysis of gene expression in tissue sections by spatial transcriptomics,” Science, Jul. 2016, 353(6294):78-82. |
| Stahl et al., “Visualization and analysis of gene expression in tissue sections by spatial transcriptomics,” Supplementary Materials, Science, Jul. 2016, 353(6294):78-82, 41 pages. |
| Stimpson et al., “Real-time detection of DNA hybridization and melting on oligonucleotide arrays by using optical wave guides,” Proc Natl Acad Sci USA, Jul. 1995, 92(14):6379-83. |
| Strell et al., “Placing RNA in context and space—methods for spatially resolved transcriptomics,” The FEBS Journal, 2019, 286(8):1468-1481. |
| Stuart et al., “Comprehensive Integration of Single-Cell Data,” Cell, Jun. 2019, 177(7):1888-1902. |
| Stubbington et al., “T cell fate and clonality inference from single cell transcriptomes,” Nature Methods, Apr. 2016, 13(4):329-332. |
| Sudmeier et al., “Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases,” Cell Reports Medicine, May 17, 2022, 3:100620, 22 pages. |
| Sun et al., “Statistical Analysis of Spatial Expression Pattern for Spatially Resolved Transcriptomic Studies,” Nature Methods, Jan. 27, 2020, 17(2): 193-200. |
| Svensson et al., “SpatialDE: identification of spatially variable genes,” Nature Methods, May 2018, 15:343-346, 15 pages. |
| Takei et al., “Integrated Spatial Genomics Reveals Global Architecture Of Single Nuclei,” Nature, Jan. 27, 2021, 590(7845):344-350, 53 pages. |
| Tegtmeyer et al., “Alternative Interactions of the SV40 A Protein with DNA,” Virology, 1981, 115:75-87. |
| Teraguchi et al., “Methods for sequence and structural analysis of B and T cell receptor repertoires,” Computational and Structural Biotechnology Journal, Jul. 17, 2020, 18:2000-2011. |
| Tijssen et al., “Overview of principles of hybridization and the strategy of nucleic acid assays” in Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, 1993, 24(Chapter 2), 65 pages. |
| Tomita et al., “Attention-Based Deep Neural Networks for Detection of Cancerous and Precancerous Esophagus Tissue on Histopathological Slides,” JAMA Network Open. Nov. 6, 2019, 2(11):e1914645, 13 pages. |
| Trejo et al., “Extraction-free whole transcriptome gene expression analysis of FFPE sections and histology-directed subareas of tissue,” PLoS ONE, Feb. 2019, 14(2):e0212031, 22 pages. |
| Tu et al., “TCR sequencing paired with massively parallel 3′ RNA-seq reveals clonotypic T cell signatures,” Nature Immunology, Dec. 2019, 20(12):1692-1699. |
| Twyman et al., “Techniques Patents for SNP Genotyping,” Pharmacogenomics, Jan. 2003, 4(1):67-79. |
| Van Gelder et al., “Amplified RNA synthesized from limited quantities of heterogeneous cDNA,” Proc. Natl. Acad. Sci. USA, 1990, 87(5):1663-1667. |
| Vasiliskov et al., “Fabrication of microarray of gel-immobilized compounds on a chip by copolymerization,” Biotechniques, Sep. 1999, 27(3):592-606. |
| Vázquez Bernat et al., “High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis,” Front Immunol., Apr. 2019, 10:660, 12 pages. |
| Vickovic et al., “High-definition spatial transcriptomics for in situ tissue profiling,” Nat Methods, Oct. 2019, 16(10):987-990. |
| Vickovic et al., “SM-Omics: An automated Platform for High-Throughput Spatial Multi-Omics,” bioRxiv, Oct. 2020, 40 pages. |
| Villa et al., “Partial V(D)J Recombination Activity Leads to Omenn Syndrome,” Cell, May 29, 1998, 93:885-896. |
| Vogelstein et al., “Digital PCR,” Proceedings of the National Academy of Sciences, Aug. 1999, 96(16):9236-9241. |
| Wade et al., “Genome sequence, comparative analysis, and population genetics of the domestic horse.,” Science., 326: 865-7, 2009. |
| Walker et al., “Strand displacement amplification—an isothermal, in vitro DNA amplification technique,” Nucleic Acids Research, 1992, 20(7):1691-1696. |
| Wang et al., “High-fidelity mRNA amplification for gene profiling,” Nature Biotechnology, Apr. 2000, 18(4):457-459. |
| Wang et al., “Imaging-based pooled CRISPR screening reveals regulators of IncRNA localization,” Proc Natl Acad Sci USA, May 2019, 116(22):10842-10851. |
| Wang et al., “Molecular probes for enriching and detecting complex nucleic acid sequences,” Nat Chem., Dec. 2017, 9(12):1222-1228. |
| Waxman et al., “De-regulation of common housekeeping genes in hepatocellular carcinoma,” BMC Genomics, 2007, 1-9. |
| Willi-Monnerat et al., “Comprehensive spatiotemporal transcriptomic analyses of the ganglionic eminences demonstrate the uniqueness of its caudal subdivision,” Molecular and Cellular Nueorsciences 37: 845-856, 2008. |
| Worthington et al., “Cloning of random oligonucleotides to create single-insert plasmid libraries,” Anal Biochem, 2001, 294(2):169-175. |
| Xia et al., “Spatial transcriptome profiling by MERFISH reveals subcellular RNA compartmentalization and cell cycle-dependent gene expression”, Proceedings of the National Academy of Sciences, Sep. 2019, 116(39):19490-19499. |
| Xiao et al., “Direct determination of haplotypes from single DNA molecules,” Nature Methods, 2009, 6(3):199-01. |
| Yershov et al., “DNA analysis and diagnostics on oligonucleotide microchips,” Proc. Natl. Acad. Sci. USA, May 1996, 93(10):4913-4918. |
| Zhang et al., “Single-base mutational analysis of cancer and genetic diseases using membrane bound modified oligonucleotides,” Nucleic Acids Res., Jul. 1991, 19(14):3929-33. |
| Zhu et al., “Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction,” Biotechniques, Apr. 2001, 30(4):892-897. |
| Zilberman et al., “Genome-wide analysis of DNA methylation patterns,” Development (2007) 134: 3959-3965. |
| Zlobec et al., “Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types,” Journal of Translational Medicine, 2013 11(104):1-7. |
| Asp et al., “A spatiotemporal organ-wide gene expression and cell atlas of the developing human heart,” Cell, Dec. 12, 2019, 179(7): 1647-1660. |
| 10xGenomics.com, [online], “Visium Spatial Gene Expression Reagent Kits—Tissue Optimization—User Guide,” Feb. 2022, retrieved on Mar. 29, 2024, retrieved from URL<https://cdn.10xgenomics.com/image/upload/v1660261286/support-documents/CG000238_VisiumSpatialTissueOptimizationUserGuide_RevE.pdf>, 46 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20240080346 A1 | Mar 2024 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63033568 | Jun 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 18315289 | May 2023 | US |
| Child | 18497415 | US | |
| Parent | 17552135 | Dec 2021 | US |
| Child | 18315289 | US | |
| Parent | PCT/US2021/035242 | Jun 2021 | WO |
| Child | 17552135 | US |
